Home› India› Ministry of Chemicals and Fertilizers› In exercise of the powers conferred by paragraphs 4 6 10 11 ...
Date: 2018-11-02 Category: Extra Ordinary State: Union Government Country: India

In exercise of the powers conferred by paragraphs 4 6 10 11 14 16 17 and 18 of the Drugs

Issued by Ministry of Chemicals and Fertilizers · Department of Pharmaceuticals

Research with AI Agent Chat with Document Generate Summary Translate Helpful Share Add to Project Create Task

Executive Summary & Key Takeaways

Executive Summary: This document comprises a series of orders issued by the National Pharmaceutical Pricing Authority (NPPA) on November 2, 2018, regarding drug price regulation. It fixes ceiling prices for scheduled formulations, revises retail prices for certain drugs, withdraws a ceiling price for Vitamin A oral liquid, and sets retail prices for various formulations. Manufacturers must comply with these price regulations and submit necessary information to the NPPA. Key Points / Main Content: Ceiling Price Fixation: * The NPPA fixes ceiling prices for scheduled formulations, excluding goods and services tax (GST), as specified in provided tables. * Manufacturers selling above the ceiling price plus GST must revise prices downward. * Existing manufacturers with MRP lower than the ceiling price plus GST must maintain their current MRP. Retail Price Revisions: * The NPPA fixes retail prices for certain formulations, excluding GST, as detailed in provided tables. * These prices apply to specific manufacturers and marketers who have submitted Form I for price fixation. * Manufacturers may add GST if it is actually paid or payable to the government. Withdrawal of Ceiling Price: * The ceiling price for Vitamin A Oral Liquid 100000 IU/ml is withdrawn due to procurement difficulties faced by state agencies. * All other ceiling prices and notes remain in operation unless specifically amended. General Manufacturer Obligations: * Manufacturers must determine pack prices based on specified ceiling prices and according to Drugs Prices Control Order (DPCO) 2013 guidelines. * Price lists must be issued in Form V to the NPPA via IPDMS, with copies to State Drug Controllers and dealers. * Manufacturers launching new drugs must apply for prior price approval from the NPPA in Form I. * Quarterly returns on production, import, and sale must be furnished to the NPPA in Form III via IPDMS. * The NPPA must be notified of any planned production discontinuation at least six months in advance using Form IV. Retailer and Dealer Responsibilities: * Retailers and dealers must display price lists and supplementary lists in a visible location on their premises. Non-Compliance: * Manufacturers not adhering to specified prices and conditions are liable to deposit overcharged amounts with interest under the Essential Commodities Act, 1955, and the DPCO 2013. Superseded Orders: * Price orders fixing ceiling or retail prices issued before the notification date are superseded by this order. Impact Analysis: Manufacturers: * Impact: Must comply with new ceiling and retail price regulations, adjust pricing strategies, and fulfill reporting requirements. * Action Required: Revise prices, submit price lists, comply with reporting obligations, and seek price approvals for new drugs. Retailers and Dealers: * Impact: Must display updated price lists and ensure prices do not exceed the regulated amounts. * Action Required: Update price displays and adhere to pricing regulations. Government (NPPA and State Drug Controllers): * Impact: Responsible for enforcing price regulations and monitoring manufacturer compliance. * Action Required: Enforce regulations, review submitted data, and take action against non-compliant entities. Consumers: * Impact: Benefit from regulated drug prices, ensuring affordability and accessibility. * Action Required: Be aware of the regulated prices and report any overcharging to the appropriate authorities.

Key Entities Referenced

Drugs Prices Control Order, 2013: A legal order issued by the Government of India to regulate the prices of drugs. National Pharmaceutical Pricing Authority: A regulatory agency of the Government of India that fixes/revises the prices of pharmaceutical products. Ministry of Chemicals and Fertilizers: A ministry in the Government of India responsible for policy-making and planning of chemicals and fertilizers industries. Essential Commodities Act, 1955: An act of the Parliament of India that ensures the supply of certain commodities, including drugs. IPDMS: Integrated Pharmaceutical Database Management System - An online system for drug manufacturers to submit information to the NPPA. Vitamin A Oral liquid: A pharmaceutical product, the ceiling price of which was initially fixed and later withdrawn under specific notifications. New Delhi: The location where the order was issued, New Delhi, Delhi Department of Pharmaceuticals: Department under the Ministry of Chemicals and Fertilizers
Official Source Record View Original Source →
See Full Document Text
jftLVªh laö Mhö ,yö&33004@99 REGD. NO. D. L.-33004/99 vlk/kj.k EXTRAORDINARY Hkkx II—[k.M 3—mi&[k.M (ii) PART II—Section 3—Sub-section (ii) izkf/dkj ls izdkf'kr PUBLISHED BY AUTHORITY la- 4426] ubZ fnYyh] 'kqØokj] uoEcj 2] 2018@dkfrZd 11] 1940 No. 4426] NEW DELHI, FRIDAY, NOVEMBER 2, 2018/KARTIKA 11, 1940 jlk;u vkSj moZjd ea=ky; ¼vkS"k/k foHkkx½ ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ vkns’k ubZ fnYyh] 2 uoEcj] 2018 dk-vk- 5633((((अअअअ)))).—Hkkjr ljdkj d s jlk;u vkSj moZjd ea=ky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk- vk- 701¼v½ rkjh[k 10 ekpZ] 2016 d s lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 d s iSjk 4, 6, 10, 11, 14, 16, 17 vkSj 18 }kjk iznRr 'kfDr;k sa dk iz;kxs djr s gq,] jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k ¼ftl s lfa{kIr :i l s ,uihih, dgk tkrk gS½ uhp s dh lkj.kh d s LrHa k ¼5½ e sa fofufnZ"V vf/kdre dher dk s mDr lkj.kh d s LrHa k ¼3½ vkSj ¼4½ e sa Øe’k%% rRLFkkuh ifzof"V;k sa e sa fofufnZ"V [kqjkd :i ,o a izcyrk vkSj bdkbZ lfgr ml lkj.kh d s LrHa k ¼2½ e sa dh rRLFkkuh ifzof"V e sa fofufnZ"V vuqlfwpr fofufeZfr;k sa e sa l s iRz ;ds dh] oLr q ,o a lsok dj] ;fn dkbs Z gS] dk s NkMs d+ j vf/kdre dher d s :i e sa fu;r djrh gS% lkj.kh Ø-l-a vuqlfwpr fofufeZfr dk [kqjkd :i ,o a izcyrk bdkbZ vf/kdre uke dher ¼#-½ (1) (2) (3) (4) (5) 1. fMesjdkizkys bta SD’ku 50 fexzk-@fefy- 1 fefy- 187.85 2. QkbVkes us kfMou xkys h 10 fexzk- 1 xkys h 13.63 ¼foVkfeu d s 1½ 3. iSjkflVkekys vksjy fyD;bw ZM 100 fexzk-@fefy- ¼iMs ªkfVd½ 1 fefy- 1.52 uksV % ¼d½ ljdkj }kjk bl idz kj fu;r dh xbZ vkSj vf/klfwpr dh xbZ vf/kdre dher ¼/ku oLrq ,o a lsok dj] tk s ykx w gk½sa l s vf/kd dher ij vuqlfwpr fofufeZfr;k sa d s czkMa Ms ;k tus fsjd ;k nkus k sa :ikarjk sa dk s cps jg s vuqlfwpr fofufefZr;k sa d s lHkh fofuekZrk] mi;qZDr lkj.kh d s LrHa k (5) e sa of.kZr vf/kdre dher ¼/ku oLrq ,o a lsok dj] tk s ykx w gk½sa l s vf/kd lHkh ,slh fofufeZr;k sa dh dher dk v/kkes [q kh iqujh{k.k djxsa As 6530 GI/2018 (1)2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ¼[k½ lHkh ektS nw k fuekZrkvk sa dk s mi;qZDr dfFkr vuqlfwpr fofufeZfr;k sa d s vf/kdre [kqnjk dher mi;qZDr lkj.kh d s LrHa k ¼5½ e sa fofufnZ"V vf/kdre dher oLrq ,o a lsok dj lfgr l s de gS rk]s tgk a dgh Hkh ykx w gk]s vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 13(2) d s vuqlkj mldk s ekStnw k vf/kdre [kqnjk dher dk s cuk, j[kuk gkxs kA ¼x½ vxj fuekZrkvk sa u s mi;qZDr lkj.kh d s LrHa k (5) e sa of.kZr vf/kdre dher ij ljdkj dk s okLro e sa Hkqxrku fd;k g S ;k ;g n;s gS rk s o s oLrq ,o a lsok dj dk s tkMs + ldr s gASa ¼?k½ vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 11 e sa fn, x, izko/kkuk sa d s rgr lEcfU/kr fuekZrkvk sa dk s mi;qZDr lkj.kh d s LrHa k ¼5½ e sa fofufnZ"V vf/kdre dher d s vk/kkj ij vuqlfwpr fofufeZfr;k sa d s iSdk sa d s fy, vf/kdre dher fu/kkZfjr djAsa fuekZrk vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 24 d s rgr QkWeZ&V e sa vf/klpw uk dh rkjh[k l s vkbZihMh,e,l d s ek/;e ls Hkjdj ,uihih, dk s ,d eYw ; lpw h tkjh dj sa rFkk mldh dkiW h jkT; vkS"kf/k fu;a=dk sa vkSj fofuekZrk forjdk sa dk s tkjh djAsa ¼³½ vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjk 24 (4) d s mic/a kk sa d s vuqlkj izR;ds QqVdj foØsrk vkSj forjd fofuekZrk }kjk fn, x, :i e sa ,sl s ifjlj] tgk a dkjkcs kj dk s bl izdkj fd;k tk jgk g S fd mll s ijke’kZ d s bPNqd fdlh O;fDr d s fy, igpqa vklku gk]s ogk a mld s fdlh lgtn`’; Hkkx ij dher lpw h vkSj iwjd lpw h] ;fn dkbs Z gk]s dk s lia znf’kZr djxs kA ¼p½ mi;qZDr lkj.kh e sa ;Fkk fofufnZ"V [kqnjk ;k icz yrk ;k nkus k sa d s lkFk vuqlfwpr fofufefZr dk dkbs Z ektS nw k fofuekZrk vkS"k/k eYw ; fu;a=.k vkn’sk] 2013 d s iSjk 2¼;½w d s vuqlkj dkbs Z ub Z vkS"kf/k dk s ykpa djrk gS rk s ,sl s ekStnw k fofuekZrk dh vkS"k/k ¼eYw ; fu;a=.k½ vkn’sk] 2013 dh vuqlpw h&II d s varxZr ;Fkk fofufnZ"V QkeZ&I e sa ,uihih, dk s ,slh ubZ vkS"kf/k d s iwoZ eYw ; vuqekns u gsrq vkons u djuk gkxs kA ¼N½ mi;qZDr vuqlfwpr fofufefZr;k sa dh mRiknu@vk;kr vkSj fcØh d s lEcU/k e sa fuekZrkvksa dk s vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s lpw h II d s QkWeZ III dk s vkbZihMh,e,l d s ek/;e l s Hkjdj ,uihih, dk s gj frekgh dh fjikVs Z izLrqr djxs kA mi;qZDr vuqlfwpr fofufeZfr;k sa d s fuekZ.k dk s dkbs Z fuekZrk mRiknu cUn dju s dk bPNqd gk s rk s bldh lpw uk ,uihih, dk s voxr djk;xs kA bld s lEcU/k e sa vxj vuqlfwpr fofufefZr;k sa d s mRiknu vkSj vk;kr dk s cUn dju s dk bPNqd gS rk s cUn dju s dh frfFk l s N% eghu s igy s lpw h II d s QkWeZ IV e sa Hkjdj ,uihih, dk s izLrqr djxs kA ¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijkDs r dfFkr lkj.kh e sa n'kkZ; s vf/kdre eYw ; vkSj 'krks± dk ikyu ugh a djrh g Sa rk s o s vko';d oLrq,¡ vf/kfu;e] 1955 d s lkFk ifBr Mhihlhvk]s 2013 d s izko/kkuk sa d s v/khu C;kt lfgr vf/kizHkkfjr jkf'k dk s tek dju s d s fy, nk;h gkxsa As ¼>½ bl vkn's k e sa mijkDs r lkj.kh d s LrHa k ¼2½ e sa dh rRLFkkuh izfof"V e sa fofufnZ"V ,slh fofufeZfr;k sa d s idS k sa dh vf/kdre dher fu;r gkus s d s ifj.kkeLo:i] vf/kdre ;k [kqnjk eYw ; fu/kkZfjr vkn's k ;fn dkbs Z gk]s tk s fd bl vkn's k l s iwoZ tkjh g,q gS] Lor% gh vf/kØe.k gk s tk;xsa sA [dk-a l-a@192@60@2018@,Q@Qk- l-a 8¼60½@2018@Mhih@,uihih,&fMoh--II] cythr flga ] lgk;d fun's kd MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals) (NATIONAL PHARMACEUTICAL PRICING AUTHORITY) ORDER New Delhi, the 2nd November, 2018 S.O. 5633(E).—In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 3 TABLE Sl. No. Name of the Scheduled Formulation Dosage form & Strength Unit Ceiling Price (Rs.) (1) (2) (3) (4) (5) 1. Dimercaprol Injection 50 mg/ml 1 ml 187.85 2. Phytomenadione Tablet 10mg 1 Tablet 13.63 (Vitamin K1) 3. Paracetamol Oral Liquid 100 mg/ml 1 ml 1.52 (pediatric) Note: (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any. (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013. (c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form- IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/192/60/2018/F /F. No. 8(60)/2018/D.P./NPPA-Div.-II] BALJIT SINGH, Asstt. Director vkns’k ubZ fnYyh] 2 uoEcj] 2018 dk-vk- 5634.—(v) Hkkjr ljdkj d s jlk;u vkSj moZjd ea=ky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk- vk- 701¼v½ rkjh[k 10 ekpZ] 2016 d s lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 d s iSjk 4, 6, 10, 11, 14, 16, 17 vkSj 18 }kjk iznRr 'kfDr;k sa dk iz;kxs djr s gq, vkSj Hkkjr ljdkj e sa jlk;u ,o a moZjd ea=ky; ¼jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k½ d s dk- vk- 1462¼v½ fnukda 2 vizSy] 2018 d s vkn’sk d s vf/kØe.k e sa tgk a rd mldk lca /a k uhp s dh lkj.kh d s fofufeZfr iSd l s gS] mu ckrk sa d s flok; vf/kØkUr djr s gq, ftUg sa ,sl s vf/kØe.k d s iwoZ fd;k x;k gS ;k dju s dk ykis fd;k x;k gS] jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k uhp s dh lkj.kh d s LrHa k ¼5½ e sa fofufnZ"V vf/kdre dher dk s mDr lkj.kh d s LrHa k ¼3½ vkSj ¼4½ e sa Øe'k% rRLFkkuh ifzof"V;k sa e sa fofufnZ"V [kqjkd :i ,o a izcyrk vkSj bdkbZ lfgr ml lkj.kh4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] d s LrHa k ¼2½ e sa dh rRLFkkuh izfof"V e sa fofufnZ"V vuqlfwpr fofufeZfr;k sa e sa l s izR;ds dh] oLr q ,o a lsok dj] ;fn dkbs Z gS] dk s NkMs d+ j vf/kdre dher d s :i e sa fu;r djrh gS% lkj.kh Ø-l-a vuqlfwpr fofufeZfr dk uke [kqjkd :i ,o a izcyrk bdkb Z vf/kdre dher ¼#-½ (1) (2) (3) (4) (5) 1. ukbVªl vkWDlkbM bugys 's ku ?ku ehVj 219.29 2. vkWDlhtu bugys 's ku ¼vkS"k/kh; xSl½ ?ku ehVj 16.47 uksV % ¼d½ ljdkj }kjk bl idz kj fu;r dh xbZ vkSj vf/klfwpr dh xbZ vf/kdre dher ¼/ku oLrq ,o a lsok dj] tk s ykx w gk½sa l s vf/kd dher ij vuqlfwpr fofufeZfr;k sa d s czkMa Ms ;k tus fsjd ;k nkus k sa :ikarjk sa dk s cps jg s vuqlfwpr fofufefZr;k sa d s lHkh fofuekZrk] mi;qZDr lkj.kh d s LrHa k (5) e sa of.kZr vf/kdre dher ¼/ku oLr q ,o a lsok dj] tk s ykx w gk½sa l s vf/kd lHkh ,slh fofufeZr;k sa dh dher dk v/kkes [q kh l’akk/s ku djxsa As ¼[k½ mi;qZDr lkj.kh ¼/ku oLrq ,o a lsok dj] tk s ykx w gS] ;fn dkbs Z gS½ d s LrHa k ¼5½ e sa fofufnZ"V vf/kdre eYw ; dh vi{s kk de [kqnjk eYw ; okyh Åij of.kZr vuqlfwpr fofufeZfr;k sa d s lHkh ekStnw k fofuekZrk Mhihlhvk]s 2013 d s iSjk 13¼2½ d s vuqlkj oLrq ,o a lsok dj d s dk;kZUo;u ij mRikn 'kYq d vkSj djk sa d s varj d s dkj.k vf/kdre [kqnjk eYw ; e sa gqbZ of`) d s vykok ekStnw k vf/kdre [kqnjk eYw ; dk s fujarj cuk, j[kxsa As ¼x½ vxj fuekZrkvk sa u s mi;qZDr lkj.kh d s LrHa k (5) e sa of.kZr vf/kdre dher ij ljdkj dk s okLro e sa Hkqxrku fd;k g S ;k ;g n;s gS rk s o s oLrq ,o a lsok dj dk s tkMs + ldr s gASa ¼?k½ vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 11 e sa fn, x, izko/kkuk sa d s rgr lEcfU/kr fuekZrkvk sa dk s mi;qZDr lkj.kh d s LrHa k ¼5½ e sa fofufnZ"V vf/kdre dher d s vk/kkj ij vuqlfwpr fofufeZfr;k sa d s iSdk sa d s fy, vf/kdre dher fu/kkZfjr djAsa fuekZrk vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 24 d s rgr QkWeZ&V e sa vf/klpw uk dh rkjh[k l s vkbZihMh,e,l d s ek/;e ls Hkjdj ,uihih, dk s ,d eYw ; lpw h tkjh dj sa rFkk mldh dkiW h jkT; vkS"kf/k fu;a=dk sa vkSj fofuekZrk forjdk sa dk s tkjh djAsa ¼M½+ vkS"k/k ¼eYw ; fu;a=.k½ vkns'k] 2013 d s 24 (4) ds mic/a kk sa d s vuqlkj iRz ;ds QqVdj foØsrk vkSj forjd fofuekZrk }kjk fn, x, :i e sa ,sl s ifjlj] tgk a dkjkcs kj dk s bl izdkj fd;k tk jgk gS fd mll s ijke'kZ d s bPNqd fdlh O;fDr d s fy, igpqa vklku gk]s ogk a mld s fdlh lgtn`’; Hkkx ij dher lpw h vkSj iwjd lpw h] ;fn dkbs Z gk]s dk s lia znf’kZr djxs kA ¼p½ mi;qZDr lkj.kh d s LrHa k ¼5½ e sa fofufnZ"V vf/kdre dher d s fy, fofufnZ"V vuqlfwpr fofufeZfr;k sa d s fofufnZ"V fofHkUu rjhd s vkSj izcyrk l s fHkUu vxj ekStnw k fuekZrkvk sa }kjk ,d ubZ vk"Skf/k dk s ykpa djrk gS rk s ml s igy s vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 2¼;½w d s vuqlkj vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s rgr lpw h II e sa fofufnZ"V QkeZ I d s ek/;e l s ,uihih, e sa eYw ; fu/kkZj.k gsrq vkons u djuk gkxs kA ¼N½ mi;qZDr vuqlfwpr fofufefZr;k sa dh mRiknu@vk;kr vkSj fcØh d s lEcU/k e sa fuekZrkvksa dk s vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s lpw h II d s QkWeZ III dk s vkbZihMh,e,l d s ek/;e l s Hkjdj ,uihih, dk s gj frekgh dh fjikVs Z izLrqr djxs kA mi;qZDr vuqlfwpr fofufeZfr;k sa d s fuekZ.k dk s dkbs Z fuekZrk mRiknu cUn dju s dk bPNqd gk s rk s bldh lpw uk ,uihih, dk s voxr djk;xs kA bld s lEcU/k e sa vxj vuqlfwpr fofufefZr;k sa d s mRiknu vkSj vk;kr dk s cUn dju s dk bPNqd gS rk s cUn dju s dh frfFk l s N% eghu s igy s lpw h II d s QkWeZ IV e sa Hkjdj ,uihih, dk s izLrqr djxs kA ¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijkDs r dfFkr lkj.kh e sa n'kkZ; s vf/kdre eYw ; vkSj 'krks± dk ikyu ugh a djrh g Sa rk s o s vko';d oLrq,¡ vf/kfu;e] 1955 d s lkFk ifBr Mhihlhvk]s 2013 d s izko/kkuk sa d s v/khu C;kt lfgr vf/kizHkkfjr jkf'k dk s tek dju s d s fy, nk;h gkxsa As ¼>½ bl vkn's k e sa mijkDs r lkj.kh d s LrHa k ¼2½ e sa dh rRLFkkuh izfof"V e sa fofufnZ"V ,slh fofufeZfr;k sa d s idS k sa dh vf/kdre dher fu;r gkus s d s ifj.kkeLo:i] vf/kdre ;k [kqnjk eYw ; fu/kkZfjr vkn's k ;fn dkbs Z gk]s tk s fd bl vkn's k l s iwoZ tkjh g,q gS] Lor% gh vf/kØe.k gk s tk;xsa sA [dk-a l-a@192@60@2018@,Q@Qk- l-a 8¼60½@2018@Mhih@,uihih,&fMoh--II] cythr flga ] lgk;d fun's kd¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 5 ORDER New Delhi, the 2nd November, 2018 S.O. 5634(E).—In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 1462(E), dated 2nd April 2018, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Sl. No. Name of the Scheduled Dosage form & Strength Unit Ceiling Formulation Price (Rs.) (1) (2) (3) (4) (5) 1. Nitrous oxide Inhalation Cubic meter 219.29 2. Oxygen Inhalation (Medicinal gas) Cubic Meter 16.47 Note: (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any. (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013. (c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule- II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/192/60/2018/F/ F. No. 8(60)/2018/D.P./NPPA-Div.-II] BALJIT SINGH, Asstt. Director6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] vkns’k ubZ fnYyh] 2 uoEcj] 2018 dk-vk- 5635(v).—vkS"k/k foHkkx }kjk vkS"k/k ¼eYw ; fu;a=.k½] 2013 d s iSjk 31 d s varxZr ikfjr ble sa uhp s lkj.kh d s LrHa k ¼6½ e sa fofufnZ"V vkn’skk sa d s }kjk tkjh iqufoZykds u vkn’skk sa d s lna Hk Z e sa fn; s x, funsZ’kk sa d s dk;kZUo;u e sa vkSj Hkkjr ljdkj d s jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekp]Z 2016 d s lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 d s iSjk 5] 11 vkSj 15 }kjk iznRr 'kfDr;k sa dk iz;kxs djr s gq,] lkj.kh d s LrHa k ¼7½ e sa fofufn"ZV Hkkjr ljdkj d s jlk;u vkSj moZjd ea=ky;] ¼jk"Vªh; vkS"k/k eYw ; fu/kkZj.k½ izkf/kdj.k d s vkn’skk sa d s vf/kØe.k e]sa tgk¡ rd mldk lEcU/k uhp s dh lkj.kh d s fofufeZfr iSdk sa l s gS] mu ckrk sa d s flok;] vf/kØkUr djr s gq, ftUg sa ,sl s vf/kØe.k d s iwo Z fd;k x;k gS ;k dju s dk ykis fd;k x;k gS] jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k ¼ftldk s lfa{kIr :i e sa ,uihih, dgk tkrk gS½] uhp s dh lkj.kh d s LrHa k ¼5½ eas fofufnZ"V [kqnjk eYw ; dk s mDr lkj.kh d s LrHa k ¼3½] ¼4½] vkSj ¼8½ e as rRLFkkuh ifzof"V;k sa e sa fofufnZ"V icz yrk] bdkbZ ¼;fwuV½ vkSj fofuekZrk vkSj foi.ku dEifu;k sa d s uke lfgr LrHa k ¼2½ e sa dh rRLFkkuh izfof"V e sa l s izR;ds dh] oLrq ,o a lsok dj] ;fn dkbs Z gS] dk s NkMs d+ j vf/kdre [kqnjk eYw ; d s :i e sa fu;r djrh gAS lkj.kh Ø- fofufeZfr dk uke [kqjkd :i ,o a bdkb Z vf/kdre iqufoZykds u ekStnw k dk- fofuekZrk vkSj l-a izcyrk dher vkn's k l-a ,o a vk- l-a ,o a foi.ku dia uh ¼#-½ rkjh[k rkjh[k (1) (2) (3) (4) (5) (6) (7) (8) 1. jkfeizhy ,eykfsMfiu xkys h izR;ds vfyfir 1 12.04 31015/02/2018- 3915(v) eSllZ yfqiu xkys h e%sa- xkys h eYw ; fu/kkZj.k fnukda fy- jkfeizhy vkbZih dh fnukda 18.12.2017 5 fexzk-] 08.06.2018 (Ø- l-a 12½ ,eykfsMfiu fclkbyVs vkbZih d s cjkcj ,eykfsMfiu 5 fexzk- 2. Qsjl ,LdksjcVs $Qkfsyd izR;ds fQYe 1 8.01 31015/08/2018- 3915(v) eSllZ fr:ifr ,flM$lkbukds kcs kykfeu$ftda fyfir xkys h xkys h eYw ; fu/kkZj.k fnukda efsMd;s j fy- lYQVs ekus kgs kbMVªs xkys h e%sa& Qsjl dh fnukda 18.12.2017 @eSllZ ¼vkWVªhu&,DlVh½ ,LdksjcVs d s 22.06.2018 (Ø-l-a 1) QkbZtj fy- cjkcj byes us Vy vk;ju 100 fexzk-] Qkfsyd ,flM vkbZih 1-5 fexzk-] Lkbukds kcs kykfeu vkbZih 15 ,elhth] ftda lYQVs ekus kgs kbMªVs vkbZih d s cjkcj byes us Vy ftda 22-5 fexzk- 3. ,eykfsMfiu$okylkVZu xkys h izR;ds fQYe 1 5.56 31015/25/2018- 793(v) eSllZ ois hd;s j ¼oSyfsEcd 80 ,,e½ fyfir xkys h xkys h eYw ; fu/kkZj.k fnukda QkekZ izk- fy- e%sa& dh fnukda 23.02.2018 @eSllZ ,eykfsMfiu 06.08.2018 (Ø-l-a 1) ,yfsEcd fclkbyVs d s QkekZL;fwVdYl cjkcj fy- ,eykfsMfiu ;,w lih 5 fexzk- 4. ,eykfsMfiu$okylkVZu xkys h izR;ds fQYe 1 8.56 31015/25/2018- 793(v) eSllZ ois hd;s j ¼oSyfsEcd 160 ,,e½ fyfir xkys h xkys h eYw ; fu/kkZj.k fnukda QkekZ izk- fy- e%sa& dh fnukda 23.02.2018 @eSllZ 06.08.2018¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 7 ,eykfsMfiu (Ø-l-a 2) ,yfsEcd fclkbyVs d s QkekZL;fwVdYl cjkcj fy- ,eykfsMfiu ;,w lih 5 fexzk- 5. vkYs eslkVZu$,eykfsMfiu$ izR;ds fQYe 1 9.15 31015/37/2018- 2398(v) eSllZ DyksjFkkyhMkus xkys h fyfir xkys h xkys h eYw ; fu/kkZj.k fnukda lk;ukds es ¼Vªk;kys ets sLV lh,p 20½ e%sa& dh fnukda 12.06.2018 QkekZL;fwVdYl vkYs eslkVZu 4-9-2018 (Ø-l-a fy-@eSll Z lu vkbZih 20 fexzk-] 10) QkekZ ,eykfsMfiu ycs ksjVs fjt fy- fclkbyVs d s cjkcj ,eykfsMfiu 5 fexzk-] DyksjFkkyhMkus vkbZih 12-5 fexzk- 6. vkYs eslkVZu$,eykfsMfiu$ izR;ds fQYe 1 16.19 31015/37/2018- 2398(v) eSllZ DyksjFkkyhMkus xkys h fyfir xkys h xkys h eYw ; fu/kkZj.k fnukda lk;ukds es ¼Vªk;kys ets sLV lh,p 40½ e%sa& dh fnukda 12.06.2018 QkekZL;fwVdYl vkYs eslkVZu 4.9.2018 (Ø-l-a fy-@eSll Z lu vkbZih 40 fexzk-] 11) QkekZ ,eykfsMfiu ycs ksjVs fjt fy-- fclkbyVs d s cjkcj ,eykfsMfiu 5 fexzk-] DyksjFkkyhMkus vkbZih 12-5 fexzk- 7. jkts qokLVkfVu $ DykfsiMkxs zys izR;ds fQYe 1 11.43 31015/37/2018- 2398(v) eSllZ I;ksj ,Ma xkys h ¼jkts qokl lhoh 10½ fyfir xkys h xkys h eYw ; fu/kkZj.k fnukda D;ksj gYs Fkd;s j e%sa& dh fnukda 12.06.2018 izk- fy-@eSllZ jkts qokLVkfVu 04.09.2018 (Ø-l-a 9) lu QkekZ 10 fexzk-] ycs ksjVs fjt fy- DykfsiMkxs zys fclqyQVs vkbZih d s cjkcj DykfsiMkxs zys 75 fexzk- uksV % ¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZy's ku d s fofuekZrk vFkkZr tk s ÞubZ Mªxß Mhihlhvk]s 2013 d s iSjkxzkQ 2¼;½w d s rgr mi;qZDr nh xbZ lkj.kh d s LrHa k ¼6½ e sa fofufnZ"V [kqnjk eYw ; fu/kkZfjr djxsa As ¼[k½ vxj fuekZrkvk sa u s mi;qZDr lkj.kh d s LrHa k (6) e sa of.kZr vf/kdre dher ij ljdkj dk s okLro e sa Hkqxrku fd;k gS ;k ;g n;s gS rk s o s oLrq ,o a lsok dj dk s tkMs + ldr s gASa ¼x½ vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 11 e sa fn, x, izko/kkuk sa d s rgr fuekZrkvk sa dk s mi;qZDr lkj.kh d s LrHa k ¼6½ e sa fofufnZ"V [kqnjk eYw ; d s vk/kkj ij vuqlfwpr fofufeZfr;k sa d s iSdk sa d s fy, [kqnjk eYw ; fu/kkZfjr djAsa fuekZrk vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 24 d s rgr QkWeZ V e sa vf/klpw uk dh rkjh[k l s ,d eYw ; lpw h ,uihih, dk s vkbZihMh,e,l d s ek/;e l s tkjh djAsa ¼?k½ vkS"k/k ¼eYw ; fu;a=.k½ vkns'k] 2013 d s 24 (4) d s mic/a kk sa d s vuqlkj iRz ;ds QqVdj foØsrk vkSj forjd fofuekZrk }kjk fn, x, :i e sa ,sl s ifjlj] tgk a dkjckj dk s bl izdkj fd;k tk jgk gS fd mll s ijke’k Z d s bPNqd fdlh O;fDr d s fy, igpqa vklku gk]s ogk a mld s fdlh lgtn`’; Hkkx ij dher lpw h vkSj iwjd lpw h] ;fn dkbs Z gk]s dk s lia znf’kZr djxs kA8 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk eYw ;½ dsoy mi;qZDr fuekZrk@foi.ku d s fy, ykx w g S tSlk fd mi;DqZ r tus sjfd@leku lajpuk okyk dkbs Z Hkh czkMa @ lca fa/kr fofufeZfr;k as dh izcyrk rFkk ljdkj }kjk fu/kkZfjr ykx w oS/kkfud vko';drkvk sa dh ifwrZ d s v/khu izklfaxd fof/k;k@sa fu;ek sa d s vUrxZr dUs nzh;@jkT; ykblfslxa vkWFkkfsjVh d s l{ke izkf/kdkjh }kjk eUs ;Qw Ds pfjxa ykblsal eta wjh d s rgr lca fa/kr fofufeZr fuekZrk@foi.ku dEifu;k a tk s vuqikyu djrh gSA ¼p½ fofuekZrk ;k foi.ku dEiuh] mijkDs r fofufeZfr;k as vkSj fofufnZ"V 'krks± dk ikyu ugh a djrh g Sa rk s o s vko';d oLr,q ¡ vf/kfu;e] 1955 d s lkFk ifBr Mhihlhvk]s 2013 d s izko/kkuk sa d s v/khu C;kt lfgr vf/kizHkkfjr jkf'k dk s tek dju s d s fy, nk;h gkxsa As [dk-a l-a@192@60@2018@,Q@Qk- l-a 8¼60½@2018@Mhih@,uihih,&fMoh--II] cythr flga ] lgk;d fun's kd ORDER New Delhi, the 2nd November, 2018 S.O. 5635(E).—In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (5) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (8) thereof; TABLE Sl. Name of the Dosage form & Unit Retail Review Order Existing Manufacturer No. Formulation Strength Price number and SO & Marketing (Rs.) date number & Company date respectively (1) (2) (3) (4) (5) (6) (7) (8) 1. Ramipril + Each uncoated tablet 1 12.04 31015/2/2018- 3915(E) M/s Lupin Amlodipine contains: Tablet Pricing dated dated Limited Tablet Ramipril IP 5mg 08.6.2018 18.12.2017 Amlodipine Besylate IP (at Sl. No. eq. to Amlodipine 5mg 12) 2. Ferrous Each film coated tablet 1 8.01 31015/8/2018- 3915(E) M/s Tirupati Ascorbate + contains: Tablet Pricing dated dated Medicare Folic Acid + Ferrous Ascorbate eq. 22.06.2018 18.12.2017 Limited / M/s Cyanocobalamin to Elemental Iron (at Sl. No. 1) Pfizer Limited + Zinc Sulphate 100mg, Folic Acid IP Monohydrate 1.5mg, tablet (Autrin- Cyanocobalamin IP 15 XT) mcg, Zinc Sulphate Monohydrate IP eq. to Elemental Zinc 22.5mg 3. Amlodipine + Each film coated tablet 1 5.56 31015/25/2018- 793(E) M/s Vapicare Valsartan Tablet contains: Tablet Pricing dated dated pharma Pvt. (Valembic 80 Amlodipine Besylate 06.08.2018 23.02.2018 Ltd. / M/s AM) eq. to Amlodipine USP (at Sl. No. Alembic 5mg, 1) Pharmaceuticals Valsartan USP 80mg Limited 4. Amlodipine + Each film coated tablet 1 8.56 31015/25/2018- 793(E) M/s Vapicare Valsartan Tablet contains: Tablet Pricing dated dated pharma Pvt. (Valembic 160 Amlodipine Besylate 06.08.2018 23.02.2018 Ltd. / M/s AM) eq. to Amlodipine USP (at Sl. No. Alembic 5mg, 2) Pharmaceuticals Valsartan USP 160mg Limited¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 9 5. Olmesartan + Each film coated tablet 1 9.15 31015/37/2018- 2398(E) M/s Synokem Amlodipine + contains: Tablet Pricing dated dated Pharmaceuticals Chlorthalidone Olmesartan IP 20mg 04.09.2018 12.6.2018 Ltd. / M/s Sun Tablet Amlodipine Besylate IP (at Sl. No. Pharma (Triolmezest CH eq. to Amlodipine 5mg 10) Laboratories 20) Chlorthalidone IP – Ltd. 12.5mg 6. Olmesartan + Each film coated tablet 1 16.19 31015/37/2018- 2398(E) M/s Synokem Amlodipine + contains: Tablet Pricing dated dated Pharmaceuticals Chlorthalidone Olmesartan IP 40mg 04.09.2018 12.6.2018 Ltd. / M/s Sun Tablet Amlodipine Besylate IP (at Sl. No. Pharma (Triolmezest CH eq. to Amlodipine 5mg 11) Laboratories 40) Chlorthalidone IP – Ltd. 12.5mg 7. Rosuvastatin + Each film coated tablet 1 11.43 31015/37/2018- 2398(E) M/s Pure and Clopidogrel contains: Tablet Pricing dated dated Cure Healthcare Tablet Rosuvastatin Calcium 04.09.2018 12.6.2018 Pvt. Ltd. / M/s (ROSUVAS CV IP eq. to Rosuvastatin (at Sl. No. Sun 10) 10mg, Clopidogrel 9) Pharmaceutical Bisulfate IP eq. to Industries Ltd Clopidogrel 75mg Note: (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail prices are applicable only to the manufacturer / marketeer as mentioned above for generic / any brand of the same composition / strength of the subject formulations, subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. [PN/192/60/2018/F/ F. No. 8(60)/2018/D.P./NPPA-Div.-II] BALJIT SINGH, Asstt. Director vkns’k ubZ fnYyh] 2 uoEcj] 2018 dk-vk- 5636. ¼v½-—vkS"k/k foHkkx }kjk vkS"k/k ¼eYw ; fu;a=.k½] 2013 d s iSjk 31 d s varxZr ikfjr ble sa uhp s lkj.kh d s LrHa k ¼6½ e sa fofufnZS"V vkn’skk sa d s }kjk tkjh iqufoZykds u vkn’skk sa d s lna HkZ e sa fn; s x, funsZ’kk sa d s dk;kZUo;u e sa vkSj Hkkjr ljdkj d s jlk;u vkSj moZjd ea=ky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk- vk- 701¼v½ rkjh[k 10 ekpZ] 2016 d s lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn’sk] 2013 d s iSjk 4, 6, 10, 11, 14, 16, 17 vkSj 18 }kjk iznRr 'kfDr;k sa dk iz;kxs djr s gq, vkSj lkj.kh d s LrHa k ¼7½ e sa fofufnZ"V Hkkjr ljdkj d s jlk;u vkSj moZjd ea=ky;] ¼jk"Vªh;10 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k½ d s vkn’skk sa d s vf/kØe.k e]sa tgk¡ rd mldk lEcU/k uhp s dh lkj.kh d s fofufefZr iSdk sa l s gS] mu ckrk sa d s flok;] vf/kØkUr djr s gq, ftUg sa ,sl s vf/kØe.k d s iwoZ fd;k x;k gS ;k dju s dk ykis fd;k x;k gS] jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k ¼ftldk s lfa{kIr :i e sa ,uihih, dgk tkrk gS½ uhp s dh lkj.kh d s LrHa k ¼5½ e sa fofufnZ"V vf/kdre dher dk s mDr lkj.kh d s LrHa k ¼3½ vkSj ¼4½ e sa Øe’k% rRLFkkuh izfof"V;k sa e sa fofufnZ"V [kqjkd :i ,o a icz yrk vkSj bdkbZ lfgr ml lkj.kh d s LrHa k ¼2½ e sa dh rRLFkkuh izfof"V e sa fofufnZ"V vuqlfwpr fofufeZfr;k sa esa l s izR;ds ij ykx w oLr q ,o a lsok dj] ;fn dkbs Z gS] dk s NkMs d+ j vf/kdre dher d s :i e sa fu;r djrh gS% lkj.kh Ø- vuqlfwpr fofufeZfr [kqjkd :i ,o a bdkb Z vf/kdre iqufoZykds u vkn’sk l-a ekStnw k dk- vk- l-a ,o a l-a dk uke izcyrk dher ¼#-½ ,o a rkjh[k rkjh[k (1) (2) (3) (4) (5) (6) (7) 1. ,Va h&VVs ul 250 vkbZ; w izfr iSd 1043.05 31015/29/2018-ihvkb-ZI 1461(v) fnukda bE;uw kXs ykcs qfyu eYw ; fu/kkZj.k dh 02.04.2018 rkjh[k 6.8.2018 (Ø- l-a 60) dk-vk- 2400 (ई) (cid:1)दनां(cid:1)कत12.6.2018 के साथ पढ़(cid:13) uksV % ¼d½ ljdkj }kjk bl idz kj fu;r dh xbZ vkSj vf/klfwpr dh xbZ vf/kdre dher ¼/ku oLrq ,o a lsok dj] tk s ykx w gk½sa l s vf/kd dher ij vuqlfwpr fofufeZfr;k sa d s czkMa Ms ;k tus fsjd ;k nkus k sa :ikarjk sa dk s cps jg s vuqlfwpr fofufefZr;k sa d s lHkh fofuekZrk] mi;qZDr lkj.kh d s LrHa k (5) e sa of.kZr vf/kdre dher ¼/ku oLr q ,o a lsok dj] tk s ykx w gk½sa l s vf/kd lHkh ,slh fofufeZr;k sa dh dher dk v/kkes [q kh l’akk/s ku djxsa As ¼[k½ mi;qZDr lkj.kh ¼/ku oLrq ,o a lsok dj] tk s ykx w gS] ;fn dkbs Z gS½ d s LrHa k ¼5½ e sa fofufnZ"V vf/kdre eYw ; dh vi{s kk de [kqnjk eYw ; okyh Åij of.kZr vuqlfwpr fofufeZfr;k sa d s lHkh ekStnw k fofuekZrk Mhihlhvk]s 2013 d s iSjk 13¼2½ d s vuqlkj oLrq ,o a lsok dj d s dk;kZUo;u ij mRikn 'kYq d vkSj djk sa d s varj d s dkj.k vf/kdre [kqnjk eYw ; e sa gqbZ of`) d s vykok ekStnw k vf/kdre [kqnjk eYw ; dk s fujarj cuk, j[kxsa As ¼x½ vxj fuekZrkvk sa u s mi;qZDr lkj.kh d s LrHa k ¼5½ e sa of.kZr vf/kdre dher ij ljdkj dk s okLro e sa Hkqxrku fd;k gS ;k ;g n;s gS rk s o s oLrq ,o a lsok dj dk s tkMs + ldr s gASa ¼?k½ vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 11 e sa fn, x, izko/kkuk sa d s rgr lEcfU/kr fuekZrkvk sa dk s mi;qZDr lkj.kh d s LrHa k ¼5½ e sa fofufnZ"V vf/kdre dher d s vk/kkj ij vuqlfwpr fofufeZfr;k sa d s iSdk sa d s fy, vf/kdre dher fu/kkZfjr djAsa fuekZrk vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 24 d s rgr QkWeZ&V e sa vf/klpw uk dh rkjh[k l s vkbZihMh,e,l d s ek/;e ls Hkjdj ,uihih, dk s ,d eYw ; lpw h tkjh dj sa rFkk mldh dkiW h jkT; vkS"kf/k fu;a=dk sa vkSj fofuekZrk forjdk sa dk s tkjh djAsa ¼³½ vkS"k/k ¼eYw ; fu;a=.k½ vkns'k] 2013 d s 24 (4) d s mic/a kk sa d s vuqlkj iRz ;ds QqVdj foØsrk vkSj forjd fofuekZrk }kjk fn, x, :i e sa ,sl s ifjlj] tgk a dkjkcs kj dk s bl izdkj fd;k tk jgk gS fd mll s ijke’kZ d s bPNqd fdlh O;fDr d s fy, igpqa vklku gk]s ogk a mld s fdlh lgtn`’; Hkkx ij dher lpw h vkSj iwjd lpw h] ;fn dkbs Z gk]s dk s lia znf’kZr djxs kA ¼p½ mi;qZDr lkj.kh d s LrHa k ¼5½ e sa fofufnZ"V vf/kdre dher d s fy, fofufnZ"V vuqlfwpr fofufeZfr;k sa d s fofufnZ"V fofHkUu rjhd s vkSj izcyrk l s fHkUu vxj ekStnw k fuekZrkvk sa }kjk ,d ubZ vk"Skf/k dk s ykpa djrk gS rk s ml s igy s vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 2¼;½w d s vuqlkj vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s rgr lpw h II e sa fofufnZ"V QkeZ I d s ek/;e l s ,uihih, e sa eYw ; fu/kkZj.k gsrq vkons u djuk gkxs kA ¼N½ mi;qZDr vuqlfwpr fofufefZr;k sa dh mRiknu@vk;kr vkSj fcØh d s lEcU/k e sa fuekZrkvksa dk s vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s lpw h II d s QkWeZ III dk s vkbZihMh,e,l d s ek/;e l s Hkjdj ,uihih, dk s gj frekgh dh fjikVs Z izLrqr djxs kA mi;qZDr vuqlfwpr fofufeZfr;k sa d s fuekZ.k dk s dkbs Z fuekZrk mRiknu cUn dju s dk bPNqd gk s rk s bldh lpw uk ,uihih, dk s voxr djk;xs kA bld s lEcU/k e sa vxj vuqlfwpr fofufefZr;k sa d s mRiknu vkSj vk;kr dk s cUn dju s dk bPNqd gS rk s cUn dju s dh frfFk l s N% eghu s igy s lpw h II d s QkWeZ IV e sa Hkjdj ,uihih, dk s izLrqr djxs kA¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 11 ¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijkDs r dfFkr lkj.kh e sa n'kkZ; s vf/kdre eYw ; vkSj 'krks± dk ikyu ugh a djrh g Sa rk s o s vko';d oLrq,¡ vf/kfu;e] 1955 d s lkFk ifBr Mhihlhvk]s 2013 d s izko/kkuk sa d s v/khu C;kt lfgr vf/kizHkkfjr jkf'k dk s tek dju s d s fy, nk;h gkxsa As ¼>½ bl vkn's k e sa mijkDs r lkj.kh d s LrHa k ¼2½ e sa dh rRLFkkuh izfof"V e sa fofufnZ"V ,slh fofufeZfr;k sa d s idS k sa dh vf/kdre dher fu;r gkus s d s ifj.kkeLo:i] vf/kdre ;k [kqnjk eYw ; fu/kkZfjr vkn's k ;fn dkbs Z gk]s tk s fd bl vkn's k l s iwoZ tkjh g,q gS] Lor% gh vf/kØe.k gk s tk;xsa sA [dk-a l-a@192@60@2018@,Q@Qk- l-a 8¼60½@2018@Mhih@,uihih,&fMoh-II] cythr flga ] lgk;d fun's kd ORDER New Delhi, the 2nd November, 2018 S.O. 5636(E).—In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table regarding formulation specified in mentioned in the table in so far as it relates to formulation pack mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes/revises the price as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation(s) specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Sl. Name of the Dosage form Unit Ceiling Review Order Existing SO number No. Scheduled & Strength Price number and date and date Formulation (Rs.) (1) (2) (3) (4) (5) (6) (7) 1. Anti-Tetanus 250IU Each Pack 1043.05 31015/29/2017-PI.I 1461(E) dated Immunoglobulin dated 6.8.2018 2.04.2018 (at Sl. No. 60) Read with corrigendum SO 2400(E) dated 12.6.2018 Note: (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any. (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013. (c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.12 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/192/60/2018/F./ F. No. 8(60)/2018/D.P./NPPA-Div.-II] BALJIT SINGH, Asstt. Director vkns’k ubZ fnYyh] 2 uoEcj] 2018 dk-vk- 5637¼v½.—vkS"k/k foHkkx }kjk vk"Sk/k ¼eYw ; fu;a=.k½ vkn’sk] 2013 d s iSjk 19 d s varxZr jlk;u ,o a moZjd ea=ky; }kjk tkjh dk- vk- 3091¼v½ fnukda 20-09-2017 d s rgr ,vkbvZ kslhMh&,MCY;,w lh,l dh QkesZfVd fjikVs Z e sa lqlxa r foi.ku vk/kkfjr vkdM+k sa dh vuqifLFkfr e sa ljdkjh [kjhn ,tfsal;k sa dh [kjhn dherk sa d s vk/kkj ij foVkfeu , vksjy fyD;bw ZM 100000 vkbZ;@w fefy- dh vf/kdre dher fu/kkfZjr dh gSA dk- vk- 1491¼v½ fnukda 02-04-2018 d s rgr vf/kdre eYw ; dk s MCY;iw hvkb Z d s vk/kkj ij ifj’kkfs/kr fd;k x;kA 02- tcfd dukZVd] if’pe cxa ky] jktLFkku] vle vkSj fcgkj dh jkT; ,tfsal;k sa u s dgk g S fd ;g ,tfsal;k a ,uihih, }kjk vf/klfwpr eYw ; d s Hkhrj vkifwrZ dju s e sa vleFkZ gSA dNq jkT;k sa u s dgk gS fd bu fofufeZfr;k sa dh vf/kizkfIr l s lca fa/kr fufonk e sa dkbs Z lIyk;j u s Hkkx ugh a fy;kA 03- tcfd mDr fofufeZfr;k a ljdkj dk LokLF; dk;ZØe gS vkSj ;g izfrLi/kkZRed ckys h d s ek/;e }kjk fd;k tk jgk gSA dqN jkT;k sa u s mRikn dk s ^^ljdkjh vkifwrZ vkSj fcØh d s fy, ugh^a^ vkSj nok d s iSd ij ycs y yxk,Aa 04- जब(cid:1)क (cid:16)वा(cid:16)(cid:18)य और प(cid:22)रवार मं(cid:24)ालय के संयु(cid:28) सिचव ने 28.09.2018 को एक बैठक बुलाई िजसम(cid:13) रा(cid:31)य एज(cid:13)िसय! "ारा (cid:1)कए गए $ितिनिध&व से कहा गया (cid:1)क दवा क( खरीद म(cid:13) दखे ी गई क(cid:22)ठनाइय! पर चचा. क( गई। 05- tcfd] Mhihlhvk]s 2013 d s rgr [kqnjk fcØh d s fy, ihVhvkj vkSj ,e,Vh l s lca fa/kr foi.ku vk/kkfjr MkVk miyC/k ugh a gS D;kfsad mRikn ,vkbZvkslhMh&,MCY;,w lh,l dh fjikVs Z d s vuqlkj [kqnjk cktkj e sa fcØh d s fy, miyC/k ugh a gSA 06- tcfd] ,uihih, u s viuh 192oh a izkf/kdj.k dh cSBd tk s fd 29-10-2018 dk s vk;kfstr dh xb Z Fkh e sa fu.kZ; fy;k fd Mhihlhvk]s 2013 d s iSjk 19 d s rgr vf/kdre eYw ; fu;r@l’akkfs/kr dh tk ldrh gS D;kfsad jkT; ,tfsal;k sa }kjk vf/kizkfIr e sa dfBukb;k sa d s dkj.k foVkfeu , vksjy fyD;bw ZM 100000 vkbZ;@w fefy- d s vf/kdre eYw ;@ifj’kkfs/kr eYw ; dk s okil yus s dk fu.kZ; fy;k gSA 07- vc] Hkkjr ljdkj d s jlk;u vkSj moZjd ea=ky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk. vk. 701¼v½ rkjh[k 10 ekpZ] 2016 d s lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 d s iSjk 19 }kjk iznRr 'kfDr;k sa dk iz;kxs djr s gq,] jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k ¼ftldk s lfa{kIr :i e sa ,uihih, dgk tkrk gS½] vf/klpw uk l[a ;k dk-vk- 1461¼v½ fnukda 02-04-2018 vkSj dk-vk- 3091¼v½ fnukda 20-09-2017 dk s bl vf/klpw uk dh frfFk l s fuEufyf[kr lhek rd vkS"kf/k dh vf/kdre eYw ; dk s okil ysrh gSA Ø-l-a fofufeZfr 1 foVkfeu , vksjy fyD;bw ZM 100000 vkbZ;@w fefy- vU; lHkh vf/kdre dher sa vkSj ukVs izpkyu e sa jgxsa s tc rd fo’k"sk :i l s l’akkfs/kr@ifj’kkfs/kr u gkAs [dk-a l-a@192@60@2018@,Q@Qk- l-a 8¼60½@2018@Mhih@,uihih,&fMoh--II] cythr flga ] lgk;d fun's kd¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 13 ORDER New Delhi, the 2nd November, 2018 S.O. 5637 (E).—Whereas the National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals, Ministry of Chemical and Fertilizers has fixed the ceiling price under paragraph 19 of the Drug (Prices Control) Order 2013, of Vitamin A Oral liquid 100000 IU/ml vide notification number SO 3091(E) dated 20.09.2017 based on the procurement prices of Government procurement agencies, in the absence of the relevant market based data in the Pharmatrac report of AIOCD-AWACS. The ceiling prices were revised on the basis of WPI vide SO 1461(E) dated 2.4.2018. 02. Whereas State agencies of Karnataka, West Bengal, Rajasthan, Assam and Bihar have stated that the agencies are not able to procure citing the inability to supply within the ceiling price notified by NPPA. Some of the states have stated that no supplier has participated in the tender for procurement of the said formulation. 03. Whereas the said formulation is the health programme of the government and the procurement is being done by competitive bidding. Some state have practice to mark the product as “Government supply and not for sale” and like label on the packs of the medicine. 04. Whereas the Joint secretary in the Ministry of Health and Family called a meeting on dated 28-09-2018 whereby the representation made by state agencies stating the difficulties observed in the procurement of the said Medicine was discussed. 05. Whereas under the DPCO 2013, the market based data like PTR and MAT for retail sale is required. Whereas the said market based data is not available, as the product is not available for sale in the retail market as per report of AIOCD AWACS. 06. Whereas the NPPA in its 192nd Authority meeting held on 29-10-2018, decided that ceiling price may be fixed/revised under para 19 of the DPCO 2013 considering the difficulties observed by the state agencies for procurement decided to withdraw the ceiling price in respect of Vitamin A Oral liquid 100000 IU/ml. 07. Now, in exercise of the powers conferred by paragraphs 19 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby withdraw the ceiling price notification number SO 1461(E) dated 2nd April 2018 and SO 3091(E) dated 20.09.2017, with effect from the date of this notification, to the extent it belong to following formulation. Sl. No. Formulation 1 Vitamin A Oral liquid 100000 IU/ml All the other ceiling prices and notes shall continue to be operation unless specifically amended/revised. [PN/192/60/2018/F. /F. No. 8(60)/2018/D.P./NPPA-Div.-II] BALJIT SINGH, Asstt. Director vkns’k ubZ fnYyh] 2 uoEcj] 2018 dk-vk- 5638¼v½.—Hkkjr ljdkj d s jlk;u vkSj moZjd ea=ky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk. vk. 701¼v½ rkjh[k 10 ekpZ] 2016 d s lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 d s iSjk 5] 11 vkSj 15 }kjk iznRr 'kfDr;k sa dk iz;kxs djrs gq,] jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k ¼ftldk s lfa{kIr :i e sa ,uihih, dgk tkrk gS½] uhp s dh lkj.kh d s LrHa k ¼6½ e as fofufn"ZV [kqnjk eYw ; dk s mDr lkj.kh d s LrHa k ¼3½] ¼4½] vkSj ¼5½ e as rRLFkkuh izfof"V;ksa e sa fofufnZ"V izcyrk] bdkbZ ¼;fwuV½ vkSj fofuekZrk vkSj foi.ku dEifu;k sa d s uke lfgr LrHa k ¼2½ e sa dh rRLFkkuh izfof"V e sa l s izR;ds dh] oLrq ,o a lsok dj] ;fn dkbs Z gS] dk s NkMs d+ j vf/kdre [kqnjk eYw ; d s :i e sa fu;r djrh gAS lkj.kh Ø- vuqlwfpr fofufeZfr dk izcyrk bdkbZ fofuekZrk vkSj foi.ku [kqnjk la- uke@czkaM dk uke daiuh ewY; ¼#-½ (1) (2) (3) (4) (5) (6) 1. Vus fsyfXyIVhu gkbMªkcs zkes kbM $ iRz;ds vfyfir fcy;s j xkys h e%sa& 1 xkys h elS lZ lk;ukds se 10.23 eVs QkfseuZ ,plh,y ¼,lvkj½ Vus fsyfXyIVhu gkbMªkcs zkes kbM gkbMªVs d s cjkcj QkekZL;fwVdYl fy-@elS lZ xkys h Vus fsyfXyIVhu 20 fexzk-] ,Fa kes ck;kQs kekZ izk- fy- eVs QkfseuZ gkbMªkDs yksjkbM vkbZih 1000 fexzk] ¼,lvkj½14 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 2. eVs QkfseuZ ,plh,y $ iRz;ds vfyfir fcy;s j xkys h e%sa& 1 xkys h elS lZ foMa ykl ck;kVs ds izk- 3.77 Xyheis hjkbM xkys h ¼les h eVs QkfseuZ gkbMªkDs yksjkbM vkbZih ¼izkys kxsa Ms fjyht fy-@elS l Z lukQs h bfaM;k ,efj;y ,e½ QkWe Z e½sa] 500 fexzk- fy- Xyheis hjkbM vkbiZ h 0-5 fexzk- 3. Vys hfelkVZ u $ DyhuhfMikbu iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ foMa ykl ck;kVs ds izk- 10.31 $ DyksjFkkyhMkus xkys h Vys hfelkVZ u vkbiZ h 40 fexzk-] fy-@elS l Z ,CckVs gYs Fkd;s j DyksjFkkyhMkus vkbiZ h 6-25 fexzk-] DyhuhfMikbu izk- fy- vkbiZ h 10 fexzk- 4. vksjy lLi’saku ds fy, iRz;ds 5 fefy- ¼iuq xBZ u d s ckn½%& 1 fefy- elS lZ flIykfy- 5.49 DyfsjFkzkes kbflu DyfsjFkzkes kbflu vkbiZ h 250 fexzk-] fVVkfu;e fMvkWDlkbM vkbiZ h¼&½ 5. Vys felkVuZ $ ,EykfsMikbu $ iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ ,dEl MªXl ,Ma 8.91 DyksjFkkyhMkus xkys h Vys felkVuZ vkbiZ h 40 fexzk-] QkekZL;fwVdYl fy-@elS lZ ¼Vys eys kbQ 3 Mh½ ,EykfsMikbu fclkbyVs vkbZih ds cjkcj fu;kes ds QkekZL;fwVdYl fy- ,EykfsMikbu 5 fexzk-] DyksjFkkyhMkus vkbiZ h 12-5 fexzk- 6. ,VksjokLVkVhu $ DykfsiMkxs yzs iRz;ds gkM Z tsyVs kbu dISlyw es%a& 1 dISlyw elS lZ foMa ykl ck;kVs ds izk- 9.50 dISlyw ,VksjokLVkVhu dfSY’k;e vkbiZ h d s cjkcj fy-@elS l Z ,CckVs gYs Fkd;s j ,VksjokLVkVhu ¼fQYe fyfir xkys h e½sa 20 fexzk-] izk- fy- DykfsiMkxs yzs ckblYQVs vkbiZ h ds cjkcj Dykis kMs kxs yzs ¼iRz;ds nks fQYe fyfir xkys h esa 37-5 fexzk]½ 75 fexzk- 7. ,ekDs lhflyhu $ ikVs fs’k;e iRz;ds vfyfir fMLijflcy xkys h e%sa& 1 xkys h elS lZ lVs dS efsMd;s j izk-fy- 7.45 Dykoyq us V xksyh ¼DykukDs lh ,ekDs lhflyhu VªhgkbMªVs ds cjkcj ,ekDs lhflyhu @elS lZ xyQk ycs ksjVs jht MhVh½ 200 fexzk-] fy- ikVs fs’k;e Dykoyq us V fMyfqVM vkbZih d s cjkcj Dykoyq fsud ,flM 28-5 fexzk- 8. VªkekMkys $ iSjklhVkekys xkys h iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ ;uw hlu QkekZL;fwVdYl 2.49 ¼Vªlkus &ih½ VªkekMkys gkbMªkDs yksjkbM vkbiZ h 37-5 fexzk-] izk- fy- iSjklhVkekys vkbiZ h 325 fexzk- 9. okXsyhcksl $ eVs QkfseuZ xkys h iRz;ds vfyfir fcy;s MZ xksyh e%sa& 1 xkys h elS lZ ;uw hlu QkekZL;fwVdYl 3.86 ¼okXsyhlkus &,e 0-3½ okXsyhcksl vkbiZ h 0-3 fexzk-] izk- fy- eVs QkfseuZ gkbMªkDs yksjkbM vkbZih 500 fexzk- ¼lLVMsa fjyht QkWeZ e½sa 10. jkts qokLVkfVu $ ,fLifju $ iRz;ds gkM Z tsyVs kbu dISlyw es%a& 1 dISlyw elS lZ lk;ukds se 11.62 DykfsiMkxs yzs dISlyw jkts qokLVkfVu dfSY’k;e vkbiZ h d cjkcj QkekZL;fwVdYl fy-@elS lZ jkts qokLVkfVu 10 fexzk- ¼iyS VS e½sa] buVkl QkekZL;fwVdYl fy- ,fLifju vkbiZ h 75 fexzk- ¼,faVªd fyfir iyS Vs e½sa DykfsiMkxs yzs ckblYQVs vkbiZ h ds cjkcj dykfsiMkxs yzs 75 fexzk- ¼iSyVs e½sa 11. ekbdkQs us kys Vs ekfsQfVy vksjy iRz;ds 5 fefy- iuq xBZ u lLi’saku e%sa& ifzr idS elS lZ ius fsl;k ck;kVs ds fy- 5238.09 lLi’saku vkbZih ekbdkQs us kys Vs ekfsQfVy vkbiZ h 1 xzke ¼1 cksry 110 xzke ikmMj QkWj vksjy lLi’saku ds lkFk 35 xzke ekbdkQs us kys Vs ekQs fsVy e½sa 12. fclkdkMs kby lIqikfstVªh iRz;ds lIqikfstVªh e%sa& 1 elS lZ esjhfM;u 18.63 fclkdkMs kby vkbiZ h 10 fexzk- lIqikfstVªh buVjizkbtht izk- fy- 13. Vys hfelkVZ u $ DyksjFkkyhMkus iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ ,dEl MªXl ,Ma 8.00 xkys h ¼Vys esykbQ lh,p 40½ Vys hfelkVZ u vkbiZ h 40 fexzk-DyksjFkkyhMkus vkbiZ h QkekZL;fwVdYl fy-@elS lZ 12-5 fexzk- fu;kes ds QkekZL;fwVdYl izk- fy- 14. DyhuhfMikbu $ Vys felkVZ u iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ I;ksj ,Ma D;ksj 10.60 xkys h Vys felkVZ u vkbiZ h 80 fexzk-] gYs Fkd;s j izk fy-@elS l Z DyhuhfMikbu 10 fexzk- ,CckVs gYs Fkd;s j izk- fy- 15. fMokyizkbs Dl xkys h ¼Mhokds iRz;ds fQYe fyfir ,DlVMsa fjyht xkys h e%sa& 1 xkys h elS lZ Lohl xkjfu;j 11.24 vkMs h 750½ fMokyizkbs Dl lkfsM;e vkbiZ h d s cjkcj ck;kVs ds @elS l Z ckds kMZ fy- okyizkbs d ,flM 750 fexzk- 16. DykVs ªhektkys $ cDs ykes Fs kklkus Øhe e%sa& 1 xzke elS lZ D;ksjVds 4.46 fMizkis hvkus Vs Øhe DykVs ªhektkys vkbiZ h 1-00% MCY;@w MCY; w Ldhud;s j@elS l Z eus dkbMa cDs ykes Fs kklkus fMizksihvkus Vs vkbiZ h 0-025% Qkek Z fy- MCY;@w MCY; w 17. Vys felkVuZ $ DyksjFkkyhMkus iRz;ds vfyfir fcy;s MZ xksyh e%sa& 1 xkys h elS lZ ,de s QkWeyZw ’sku izk- fy- 7.71 xkys h ¼Øhlkj lhVh½ Vys felkVuZ vkbiZ h 40 fexzk-] @elS lZ flIyk fy- DyksjFkkyhMkus vkbiZ h 6-25 fexzk- 18. cDS ykQs us vksjy lkys ’qku iRz;ds 5 fefy- e%sa& 1 fefy- elS lZ lu QkekZL;fwVdYl 1.42 cDS ykQs us vkbiZ h 5 fexzk- bMa LVªht fy-@ elS l Z lu¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 15 Qkek Z ycs ksjVs jht fy- 19. Xyheis hjkbM $ eVs QkfseuZ iRz;ds vfyfir fcy;s MZ xksyh e%sa& 1 xkys h elS lZ lu QkekZ ycs ksjVs jht 6.99 gkbMªkDs yksjkbM xkys h eVs QkfseuZ gkbMªkXsyheis hjkbM $ eVs QksfeuZ fy- gkbMªkDs yksjkbM vkbiZ h ¼izkys ksaxM fjyht e½sa 500 fexzk- XyhesihjkbM vkbiZ h 3 fexzk- 20 Xyheis hjkbM $ eVs QkfseuZ iRz;ds vfyfir fcy;s MZ xksyh e%sa& 1 xkys h elS lZ lu QkekZ ycs ksjVs jht 8.58 gkbMªkDs yksjkbM xkys h eVs QkfseuZ gkbMªkDs yksjkbM vkbZih ¼izkys kxsa M fjyht fy- e½sa 500 fexzk- Xyheis hjkbM vkbiZ h 4 fexzk- 21. Xyheis hjkbM $ eVs QkfseuZ iRz;ds vfyfir fcy;s MZ xksyh e%sa& 1 xkys h elS lZ lu QkekZ ycs ksjVs jht 9.78 gkbMªkDs yksjkbM xkys h eVs QkfseuZ gkbMªkDs yksjkbM vkbZih ¼izkys kxsa M fjyht fy- e½sa 1000 fexzk- Xyheis hjkbM vkbiZ h 4 fexzk- 22. eVs QkfseuZ ,plh,y $ iRz;ds vfyfir fcy;s MZ xksyh e%sa& 1 xkys h elS lZ ,sjht ykbQlkbla ht 5.78 XyhDyktkbM$fi;kXsyhVktkus eVs QkfseuZ gkbMªkDs yksjkbM vkbZih ¼lLVMsa fjyht fy- xkys h e½sa 500 fexzk-] XyhDyktkbM vkbiZ h ¼lLVMsa fjyht es½a 30 fexzk-] fi;kXsyhVktkus ,plh,y ds cjkcj fi;kXsyhVktkus 15 fexzk- 23. eVs QkfseuZ ,plh,y $ iRz;ds vfyfir fcy;s MZ xksyh e%sa& 1 xkys h elS lZ ,sjht ykbQlkbla ht 8.29 XyhDyktkbM $ fi;kXsyhVktkus eVs QkfseuZ gkbMªkDs yksjkbM vkbZih ¼lLVMsa fjyht fy- xkys h e½sa 500 fexzk- XyhDyktkbM vkbiZ h ¼lLVMsa fjyht e½sa 60 fexzk-] fi;kXsyhVktkus ,plh,y ds cjkcj fi;kXsyhVktkus 15 fexzk- 24. DyksjFkkyhMkus $ Vys hfelkVZ u iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ thd,s e U;w 7.71 xkys h ¼Vys lkj lh,p 40@6-25½ DyksjFkkyhMkus vkbiZ h 6-25 fexzk-] Qkek@Z elS lZ VkWjVsa Vys hfelkVZ u vkbiZ h 40 fexzk- QkekZL;fwVdYl fy- 25. DyksjFkkyhMkus $ Vys hfelkVZ u iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ thd,s e U;w Qkek Z @ 8.03 xkys h ¼Vys lkj lh,p 40@12-5½ DyksjFkkyhMkus vkbiZ h 12-50 fexzk-] elS lZ VkWjVsa QkekZL;fwVdYl Vys hfelkVZ u vkbiZ h 40 fexzk- fy- 26. DyksjFkkyhMkus $ Vys hfelkVZ u iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ thd,s e U;w Qkek Z @ 13.91 xkys h ¼Vys lkj lh,p 80@12-5½ DyksjFkkyhMkus vkbiZ h 12-50 fexzk-] elS lZ VkWjVsa QkekZL;fwVdYl Vys hfelkVZ u vkbiZ h 80 fexzk- fy- 27. fMokyizk,s Dl xkys h ¼fMokds iRz;sd fQYe fyfir ,DlVMsa Ms fjyht xksyh e%sa 1 xkys h elS lZ Lohl xkjfu;j 5.45 vkMs h 250 fexzk-½ fMokyizk,s Dl lkfsM;e vkbiZ h d s cjkcj ck;kVs ds @ elS lZ ckds kMZ okyizkbs d ,flM 250 fexzk- fy- 28. okXsyhcksl $ eVs QkfseuZ xkys h iRz;ds vfyfir xkys h e%sa& 1 xkys h elS lZ ,sjht ykbQlkbla ht 6.57 okXsyhcksl vkbiZ h 0-2 fexzk-] fy- eVs QkfseuZ ,plh,y vkbiZ h 500 fexzk- 29. ,ekDs lhflyhu $ ikVs fs’k;e iRz;ds dkWEchidS e%sa& 1 fefy- elS lZ ,dEl MªXl ,Ma 3.16 Dykoyq uVs MªkbZ lhji ,½ ,ekDs lhflyhu ,Ma ikVs fs’k;e DykoqyuVs vksjy QkekZL;fwVdYl fy-@elS lZ ¼Cyew kDs l&lh, QksjV½ lLi’saku vkbZih Cy w Øksl ycs ksjVs jht izk- fy- iRz;ds 5 fefy- lLi’saku esa ,ekDs lhflyhu VªhgkbMªVs vkbiZ h ds cjkcj ,ekDs lhflyhu 400 fexzk- ikVs fs’k;e fMyVq Ms vkbiZ h Dykoqykfud ,flM 57 fexkz- ch½ 1 ok;y LVfsjy okVj QkWj bta DS ’ku vkbiZ h iRz;ds ok;y LVfsjy okVj QkWj batDS ’ku vkbiZ h 30 fefy- esa 30. jkts qokLVkfVu $ ,fLifju $ iRz;ds gkM Z tsyVs kbu dISlyw es%a& 1 dISlyw elS lZ lk;ukds se 17.88 DykfsiMkxs yzs dISlyw jkts qokLVkfVu dfSY’k;e vkbiZ h ds cjkcj QkekZL;fwVdYl fy-@elS lZ jkts qokLVkfVu 20 fexzk- ¼iyS Vs e½sa] ,eD;ksj QkekZL;fwVdYl fy- ,fLifju vkbiZ h 75 fexzk- ¼,faVªd fyfir iyS Vs e½sa] DykfsiMkxs yzs ckblYQVs vkbiZ h ds cjkcj DykfsiMkxs yzs 75 fexzk- ¼iSyVs e½sa 31. jkts qokLVkfVu $ ,fLifju $ iRz;ds gkM Z tsyVs kbu dISlyw es%a& 1 dISlyw elS lZ lk;ukds se 11.62 DykfsiMkxs yzs dISlyw jkts qokLVkfVu dfSY’k;e vkbiZ h ds cjkcj QkekZL;fwVdYl fy-@elS lZ jkts qokLVkfVu 10 fexzk- ¼iyS Vs e½sa] ,eD;ksj QkekZL;fwVdYl fy- ,fLifju vkbiZ h 75 fexzk- ¼,faVªd fyfir iyS Vs e½sa] DykfsiMkxs yzs ckblYQVs vkbiZ h ds cjkcj DykfsiMkxs yzs 75 fexzk- ¼iSyVs e½sa16 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 32. fMDykQs us d $ oftuZ fyulhM tys e%sa& 1 xzke elS lZ ,dEl MªXl ,Ma 2.41 vkW;y $ feFkkby lys hlkbyVs fMDykQs us d QkekZL;fwVdYl fy-@elS lZ $ eus Fkksy $ dis lkblhu tys MkbFkkbykekbu chih 1-16% ¼fMDykQs sud ,CckVs gYs Fkd;s j izk- fy- ¼fMDykQs es gkWV½ lkfsM;e 1% MCY;@w MCY;w ds cjkcj½] oftuZ fyulhM vkW;y chih 3% MCY;w@MCY; w ¼e[q ; :i ls vYQk fyukys fsud ,flM½ feFkkby lys hlkbyVs vkbiZ h 10% MCY;@w MCY; w ] eus Fkkys vkbiZ h 5%, dis lkblhu ;,w lih 0-0255 MCY;@w MCY; w 33. DykVs ªhektkys $ fyxukds us b;Z j MªIsl es%a& 1 fefy- elS lZ ,dEl MªXl ,Ma 5.27 b;Z j MªkIsl ¼Vªhcus ½ DykVs ªhektkys vkbiZ h 1% MCY;@w oh] QkekZL;fwVdYl fy-@elS lZ fyxukds us gkbMªkDs yksjkbM vkbiZ h 2-0% tus cqjDV QkekZL;fwVdYl fy- MCY;@w oh 34. fVekys kys $ czhutkys kekbM iRz;ds fefy- e%sa& 2 fefy- elS lZ ,tra k QkekZ fy- 283.25 vkb Z MªkIsl czhutkys kekbM vkbiZ h 1-0% MCY;@w oh] fVekys kys eys Vs vkbiZ h d s cjkcj fVekys kys 0-5% MCY;@w oh] cus tYdkfsu;e DyksjkbM vkbiZ h 0-01% MCY;@w oh ¼itzs jofsVo es½a 35. fMDykQs us d $ feFkkby $ ‘'kkfey g%S& ifzr idS elS lZ lu QkekZL;fwVdYl 125.00 eFsa kkys tyS ¼okys huh eDS l tyS ½ fMDykQs us d MkbFkkbykekbu chih 2-32% ¼20xzke½ bMa LVªht fy MCY;@w MCY; w ¼fMDykQs us d lkfsM;e 2% MCY;@w MCY;½w] feFkkby lylkbyVs vkbiZ h 10% MCY;@w MCY; w ,Ma esFa kkys vkbiZ h 5% MCY;@w MCY; w 36. fMDykQs us d $ feFkkby $ ‘'kkfey g%S& ifzr idS elS lZ lu QkekZL;fwVdYl 187.50 eFsa kkys tyS ¼okys huh eDS l tyS ½ fMDykQs us d MkbFkkbykekbu chih 2-32% ¼30xzke½ bMa LVªht fy MCY;@w MCY; w ¼fMDykQs us d lkfsM;e 2% MCY;@w MCY;½w] feFkkby lylkbyVs vkbiZ h 10% MCY;@w MCY; w ,Ma esFa kkys vkbiZ h 5% MCY;@w MCY; w 37. vkYs eslkVuZ $ ,EykfsMikbu $ iRz;ds fQYe fyfir xkys h esa%& 1 xkys h elS lZ thd,s e U;w Qkek Z fy-@ 9.585 DyksjFkkyhMkus xkys h vkYs eslkVuZ eMs kDs lkfsey 20 fexzk-] elS lZ ;uw hdse ycs ksjVs jht fy- ¼Vªh;kVs ys lkj 20½ DyksjFkkyhMkus vkbiZ h 6-25 fexzk-] ,EykfsMikbu fclkbyVs vkbZih ds cjkcj ,EykfsMikbu 5 fexzk- xkys h 38. vkYs eslkVuZ $ ,EykfsMikbu $ iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ thd,s e U;w Qkek Z fy-@ 15.61 DyksjFkkyhMkus xkys h vkYs eslkVuZ eMs kDs lkfsey 40 fexzk-] elS lZ ;uw hdse ycs ksjVs jht fy- ¼Vªh;kVs ys lkj 40½ DyksjFkkyhMkus vkbiZ h 6-25 fexzk-] ,EykfsMikbu fclkbyVs vkbiZ h d s cjkcj ,EykfsMikbu 5 fexzk- xkys h 39. ykslkjVu $ DyksjFkkyhMkus $ iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ thd,s e U;w Qkek Z fy-@ 6.36 ,eykfsMikbu xkys h ¼Vªhykslkj ykslkjVu ikVs fs’k;e vkbiZ h 50 fexzk-] elS lZ ;uw hdse ycs ksjVs jht fy- 6-25½ DyksjFkkyhMkus vkbiZ h 6-25 fexzk-] ,eykfsMikbu fclkbyVs vkbiZ h ds cjkcj ,eykfsMikbu 5 fexzk xkys h 40. ykslkjVu $ DyksjFkkyhMkus $ iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ thd,s e U;w Qkek Z fy-@ 6.41 ,eykfsMikbu xkys h ¼Vªhykslkj ykslkjVu ikVs fs’k;e vkbiZ h 50 fexzk-] elS lZ ;uw hdse ycs ksjVs jht fy- 6-25½ DyksjFkkyhMkus vkbiZ h 12-50 fexzk-] ,eykfsMikbu fclkbyVs vkbiZ h ds cjkcj ,eykfsMikbu 5 fexzk xkys h 41. Mk:ukohj $ fjVkus kohj xkys h iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ ,eD;ksj QkekZL;fwVdYl 172.52 Mk:ukohj bFkkukys Vs d s cjkcj Mk:ukohj 600 fy- fexzk- ,Ma fjVkus kohj vkbiZ h 100 fexzk- xkys h 42. Vys hfelkVZ u $ ,eykfsMikbu $ iRz;ds vfyfir fcy;s MZ xksyh e%sa& 1 xkys h elS lZ ,;kus QkWewyZ ’sku izk- fy- 8.91 DyksjFkkyhMkus xkys h ¼Vktykds Vys hfelkVZ u vkbiZ h 40 fexzk-] @elS lZ ;,w loh izk- fy- ,lh 12-5½ ,eykfsMikbu fclkbyVs vkbiZ h ds cjkcj ,eykfsMikbu 5 fexzk-] DyksjFkkyhMkus vkbiZ h 12-5 fexzk-¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 17 43. Mk:ukohj $ fjVkus kohj xkys h iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ ekbyu ycs ksjVs jht izk- 123.71 ¼MqjkjV&vkj450½ Mk:ukohj 400 fexzk- ,Ma fy-@elS l Z ekbyu QkekZL;fwVdYl izk- fy- fjVkus kohj 50 fexzk- xkys h 44. fMDykQs us d $ feFkkby $ ‘'kkfey g%S& 1 xzke elS lZ nh enzkl 2.46 eFsa kkys h lylkbyVs $ fMDykQs us d MkbFkkbykekbu chih 1-16% QkekZL;fVdYl@elS lZ Cyw eQs us fslu $ tyS Vqjius fVu Øksl ycs ksjVs jht izk- fy- MCY;@w MCY; w ¼fMDykQs us d lkfsM;e 1% vkW;y ¼fMDykVs y ,evkj tyS ½ MCY;@w MCY;½w] feFkkby lylkbyVs vkbiZ h 5% MCY;w@MCY; w ] eQs us fslu vkbiZ h 85-5% MCY;w@MCY;]w eFsa kkys vkbiZ h 2% MCY;w@MCY;]w Vqjius fVu vkW;y chih 3% MCY;@w MCY; w 45. ykehoMq hu $ Vus kQs ksohj $ iRz;ds vfyfir xkys h e%sa& 1 xkys h elS lZ ,eD;ksj 114.06 Mkys xq Vs ªkohj xkys h ykehoMq hu vkbiZ h 300 fexzk-] Vus kQs ksohj QkekZL;fwVdYl fy- fMlkis zkDs lhy Qeq kjVs vkbiZ h 300 fexzk- d s cjkcj Vus kQs ksohj fMlkis zkDs lhy 245 fexzk-] Mkys qxVs ªkohj lkfsM;e ds cjkcj Mkys qxVs ªkohj 50 fexzk- 46. Mk:ukohj $ fjVkus kohj xkys h iRz;ds fQYe fyfir e%sa& 1 xkys h elS lZ gVs sjks ycS l fy-@elS l Z 212.91 ¼Mkukohj vkj½ Mk:ukohj bFkkukys Vs d s cjkcj Mk:ukohj 800 gVs sjk s gYs Fkd;s j fy- fexzk-] fjVkus kohj 100 fexzk- xkys h 47. ykfeoMq kbu $ Vus kQs ksohj $ iRz;ds vfyfir xkys h e%sa& 1 xkys h elS lZ ekbyu ycs ksjVs jht 114.06 Mkys xq Vs ªkohj ¼,fØIVsxk½ ykehoMq hu vkbiZ h 300 fexzk-] Vus kQs ksohj fy-@elS l Z ekbyu QkekZL;fwVdYl izk- fy- fMlkis zkDs lhy Qeq kjVs vkbZih 300 fexzk-] Mkys xq Vs ªkohj lkfsM;e ds cjkcj Mksyxq Vs ªkohj 50 fexzk- 48. MDs ykVklohj $ lkQs ksLcqohj iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ ukVdks QkekZ fy- 556.442 xkys h ¼gis lhukV Iyl½ MDs ykVklohj fMgkbMªkDs yksjkbM d s cjkcj fMDykVklohj 60 fexzk-] lkQs ksLcqohj 400 fexzk- 49. MDs ykVklohj $ lkQs ksLcqohj iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ ukVdks QkekZ fy-@ 556.442 xkys h MDs ykVklohj fMgkbMªkDs yksjkbM d s cjkcj elS lZ dfSMyk gYs Fkd;s j fy- fMDykVklohj 60 fexzk-] lkQs ksLcqohj 400 fexzk- 50. MDs ykVklohj $ lkQs ksLcqohj iRz;ds fQYe fyfir xkys h e%sa& 1 xkys h elS lZ ekbyu ycs ksjVs jht izk- 556.442 xkys h ¼ekbgZ is Mohj½ MDs ykVklohj fMgkbMªkDs yksjkbM d s cjkcj fy-@elS l Z ekbyu QkekZL;fwVdYl izk- fy- fMDykVklohj 60 fexzk-] lkQs ksLcqohj 400 fexzk- 51. fMDykQs us d $ efsFky $ eFSa kkys 'kkfey g%S& ifzr idS elS lZ lu QkekZL;fwVdYl 93.75 tyS ¼okys huh eDS l tyS ½ fMDykQs us d MkbFkkbykekbu chih 2-32% ¼15xzke½ bMa LVªht fy- MCY;@w MCY; w ¼fMDykQs us d lkfsM;e 2% MCY;@w MCY;½w] feFkkby lylkbyVs vkbiZ h 10% MCY;w @ MCY;]w eFsa kkys 5% MCY;w@MCY;]w 52. fMDykQs us d $ efsFky $ eFSa kkys 'kkfey g%S& ifzr idS elS lZ lu QkekZL;fwVdYl 62.50 tyS ¼okys huh eDS l tyS ½ fMDykQs us d MkbFkkbykekbu chih 2-32% ¼10xzke½ bMa LVªht fy- MCY;@w MCY; w ¼fMDykQs us d lkfsM;e 2% MCY;@w MCY;½w] feFkkby lylkbyVs vkbiZ h 10% MCY;w@MCY; w ] eFsa kkys 5% MCY;w@MCY;]w 53. lQs Vªh,Dlkus 1 xzke IYl iRz;ds bta DS ’ku ok;y e%sa& 1 ok;y elS lZ buksok dis Vso izk- fy- 136.11 Vts kcs Ds Ve 125 fexzk- bta DS ’ku lQs Vªh,Dlkus lkfsM;e vkbiZ h d s cjkcj @elS lZ ,eD;ksj QkekZL;fwVdYl fy- lQs Vªh,Dlkus 1 xzke] Vts kcs Ds Ve lkfsM;e d s cjkcj Vts kscDs Ve 125 fexzk- 54. lQs ikMs kDs lhe $ ikVs fs’k;e MªkbZ iRz;ds 5 fefy- iuq xBZ u lLi’saku e%sa& 1 fefy- elS lZ gVs sjks ycS l fy-@elS l Z 2.40 flji ¼lQs kis zkDs l lhoh½ lQs ikMs kDs lhe izkDs lfsVy vkbiZ h ds cjkcj flIyk fy- lQs ikMs kDs lhe 50 fexzk-] ikVs fs’k;e Dykoyq us Vs fMyfqVM d s cjkcj18 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Dykoyq us Vs ,flM 31-25 fexzk- 55. lQs ikMs kDs lhe $ ikVs fs’k;e MªkbZ iRz;ds 5 fefy- iuq xBZ u lLi’saku e%sa& 1 fefy- elS lZ gVs sjks ycS l fy-@elS l Z 3.72 flji ¼lQs kis zkDs l lhoh½ lQs ikMs kDs lhe izkDs lfsVy vkbiZ h ds cjkcj flIyk fy- lQs ikMs kDs lhe 100 fexzk-] ikVs fs’k;e Dykoyq us Vs fMyfqVM d s cjkcj Dykoyq us Vs ,flM 62-50 fexzk- uksV % ¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZy's ku d s fofuekZrk vFkkZr tk s ÞubZ Mªxß Mhihlhvk]s 2013 d s iSjkxzkQ 2¼;½w d s rgr mi;qZDr nh xbZ lkj.kh d s LrHa k ¼6½ e sa fofufnZ"V [kqnjk eYw ; fu/kkZfjr djxsa As ¼[k½ vxj fuekZrkvk sa u s mi;qZDr lkj.kh d s LrHa k (6) e sa of.kZr vf/kdre dher ij ljdkj dk s okLro e sa Hkqxrku fd;k gS ;k ;g n;s gS rk s o s oLrq ,o a lsok dj dk s tkMs + ldr s gASa ¼x½ vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 11 e sa fn, x, izko/kkuk sa d s rgr fuekZrkvk sa dk s mi;qZDr lkj.kh d s LrHa k ¼6½ e sa fofufnZ"V [kqnjk eYw ; d s vk/kkj ij vuqlfwpr fofufeZfr;k sa d s iSdk sa d s fy, [kqnjk eYw ; fu/kkZfjr djAsa fuekZrk vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s iSjkxzkQ 24 d s rgr QkWeZ V e sa vf/klpw uk dh rkjh[k l s ,d eYw ; lpw h ,uihih, dk s vkbZihMh,e,l d s ek/;e l s tkjh djAsa ¼?k½ vkS"k/k ¼eYw ; fu;a=.k½ vkns'k] 2013 d s 24 (4) d s mic/a kk sa d s vuqlkj iRz ;ds QqVdj foØsrk vkSj forjd fofuekZrk }kjk fn, x, :i e sa ,sl s ifjlj] tgk a dkjckj dk s bl izdkj fd;k tk jgk gS fd mll s ijke’k Z d s bPNqd fdlh O;fDr d s fy, igpqa vklku gk]s ogk a mld s fdlh lgtn`’; Hkkx ij dher lpw h vkSj iwjd lpw h] ;fn dkbs Z gk]s dk s lia znf’kZr djxs kA ¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk eYw ;½ dsoy mi;qZDr fuekZrk@foi.ku d s fy, ykx w gS tSlk fd mUgkusa s vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 d s rgr vuqc) eYw ; fu/kkZj.k@l'a kk/s ku d s fy, QkWe Z I ij tek fd;k x;k Fkk vkSj ljdkj }kjk fu/kkfZjr lHkh ykx w oS/kkfud vko';drkvk sa dh ifwrZ d s v/khu izklfaxd fof/k;k@sa fu;ek sa d s vUrxZr tSlk fd dUs nzh;@jkT; ykblfslxa vkWFkkfsjVh d s l{ke izkf/kdkjh }kjk eUs ;Qw Ds pfjxa ykblsal eta wjh d s rgr lca fa/kr fofufeZr fuekZrk@foi.ku dEifu;k a tk s vuiq kyu djrh gAS ¼p½ fofuekZrk ;k foi.ku dEiuh] mijkDs r fofufeZfr;k as vkSj fofufnZ"V 'krks± dk ikyu ugh a djrh g Sa rk s o s vko';d oLr,q ¡ vf/kfu;e] 1955 d s lkFk ifBr Mhihlhvk]s 2013 d s izko/kkuk sa d s v/khu C;kt lfgr vf/kizHkkfjr jkf'k dk s tek dju s d s fy, nk;h gkxsa As ¼N½ bl vkn's k e sa mijkDs r lkj.kh d s LrHa k ¼2½ e sa dh rRLFkkuh izfof"V e sa fofufnZ"V fofufeZfr;k sa d s iSdk sa dh [kqnjk eYw ; fu;r gkus s d s ifj.kkeLo#i] vkn's k tk s fd bl vkn's k l s iwoZ tkjh g,q gS] Lor% gh fujLr gk s tk;xsa sA [dk-a l-a@192@60@2018@,Q@Qk- l-a 8¼60½@2018@Mhih@,uihih,&fMoh--II] cythr flga ] lgk;d fun's kd ORDER New Delhi, the 2nd November, 2018 S.O. 5638 (E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 19 TABLE Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Marketing Company Price Brand Name (Rs.) (1) (2) (3) (4) (5) (6) 1. Teneligliptin Each uncoated bilayer tablet 1 Tablet M/s Synokem 10.23 Hydrobromide + contains: Pharmaceuticals Ltd. / Metformin HCL Teneligliptin Hydrobromide Hydrate M/s Anthem Biopharma (SR) Tablet eq. to Teneligliptin 20 mg Pvt. Ltd. Metformin Hydrochloride IP 1000 mg (SR) 2. Metformin HCL + Each uncoated bilayer tablet 1 Tablet M/s Windlass Biotech 3.77 Glimepiride Tablet contains: Pvt. Ltd. (Semi Amaryl M) Metformin Hydrochloride IP (in / M/s Sanofi India Ltd. prolonged release form) 500 mg Glimepiride IP 0.5 mg 3. Telmisartan + Each film coated tablet contains: 1 Tablet M/s Windlass Biotech 10.31 Cilnidipine + Telmisartan IP 40 mg Pvt. Ltd / M/s Abbott Chlorthalidone Chlorthalidone IP 6.25 mg Healthcare Pvt. Ltd tablet Cilnidipine IP 10 mg 4. Clarithromycin for Each 5ml (after reconstitution) 1 ML M/s Cipla Limited 5.49 Oral Suspension contains: Clarithromycin IP 250mg, Titanium Dioxide IP (-). 5. Telmisartan + Each film coated tablet contains: 1 Tablet M/s Akums Drugs & 8.91 Amlodipine + Telmisartan IP 40 mg pharmaceuticals Ltd / Chlorthalidone Amlodipine Besylate IP eq. to M/s Neomac Tablet (Telmelife Amlodipine 5 mg Pharmaceuticals Pvt. 3D) Chlorthalidone IP 12.5 mg Ltd 6. Atorvastatin + Each hard gelatin capsule contains: 1 Capsule M/s Windlas Biotech 9.50 Clopidogrel Atorvastatin Calcium IP eq. to Ltd. / M/s Abbott Capsule Atorvastatin (As film coated tablet) Healthcare Pvt. Ltd. 20 mg Clopidogrel Bisulphate IP eq. to Clopidogrel (as two film coated tablet each containing 37.5mg) 75 mg 7. Amoxycillin + Each uncoated dispersible tablet 1 Tablet M/s Saitech Medicare 7.45 Potassium contains: Pvt. Ltd. / M/s Galpha Clavulante tablet Amoxycillin Trihydrate eq. to Laboratories Ltd. (Clanoxy DT) Amoxycillin 200mg Potassium Clavulante Diluted IP eq. to Clavulanic Acid 28.5mg 8. Tramadol + Each film coated tablet contains: 1 Tablet M/s Unison 2.49 Paracetamol Tablet Tramadol Hydrochloride IP 37.5 mg Pharmaceuticals Pvt. (Trson-P) Paracetamol IP 325 mg Ltd. 9. Voglibose + Each uncoated bilayered tablet 1 Tablet M/s Unison 3.86 Metformin Tablet contains: Pharmaceuticals Pvt. (Voglyson-M 0.3) Voglibose IP 0.3 mg Ltd. Metformin Hydrochloride IP 500 mg (as sustained release form) 10. Rosuvastatin + Each hard gelatin capsules contains: 1 Capsule M/s Synokem 11.62 Aspirin + Rosuvastatin Calcium IP eq. to Pharmaceuticals Ltd. / Clopidogrel Rosuvastatin 10 mg (as pellets) M/s Intas Capsules Aspirin IP 75 mg (as enteric coated Pharmaceuticals Ltd. pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg (as pellets) 11. Mycophenolate Each 5 ml of reconstituted Each Pack M/s Panacea Biotec 5238.09 Mofetil Oral suspension contains: Ltd. Suspension IP Mycophenolate Mofetil IP 1 g, (1 bottle with 110gm powder for oral20 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] suspension containing 35gm Mycophenolate Mofetil) 12. Bisacodyl Each Suppository contains: 1 M/s Meridian 18.63 Suppository Bisacodyl IP 10 mg Suppository Enterprises Pvt. Ltd. 13. Telmisartan + Each film coated tablet contains: 1 Tablet M/s Akum Drugs & 8.00 Chlorthalidone Telmisartan IP 40 mg Pharmaceuticals Ltd. / Tablet (Telmelife Chlorthalidone IP 12.5 mg M/s Neomac CH 40) Pharmaceuticals Pvt. Ltd. 14. Cilnidipine + Each film coated tablet contains: 1 Tablet M/s Pure and Cure 10.60 Telmisartan Tablet Telmisartan IP 80 mg Healthcare Pvt. Ltd. / Cilnidipine 10 mg M/s Abbott Healthcare Pvt. Ltd. 15. Divalproex Tablet Each film coated extended release 1 Tablet M/s Swiss Garnier 11.24 (Diwok OD 750 tablet contains: Biotech / M/s mg) Divalproex Sodium IP eq. to Wockhardt Ltd. Valproic Acid 750 mg 16. Clotrimazole + Cream contains: 1 GM M/s Curetech Skincare / 4.46 Beclomethasone Clotrimazole IP 1.00% w/w M/s Mankind Pharma Dipropionate Cream Beclomethasone Dipropionate IP Ltd. 0.025% w/w 17. Telmisartan + Each uncoated bilayered tablet 1 Tablet M/s Acme Formulations 7.71 Chlorthalidone contains: Pvt. Ltd. / M/s Cipla Tablet (Cresar CT) Telmisartan IP 40 mg Ltd. Chlorthalidone IP 6.25 mg 18. Baclofen Oral Each 5 ml contains: 1 ML M/s Sun Pharmaceutical 1.42 Solution Baclofen IP 5 mg Industries Ltd. / M/s Sun Pharma Laboratories Ltd. 19. Glimepiride + Each uncoated bilayered tablet 1 Tablet M/s Sun Pharma 6.99 Metformin contains: Laboratories Ltd. Hydrochoride Tablet Metformin Hydrochoride IP (as prolonged release) 500 mg Glimepiride IP 3 mg 20 Glimepiride + Each uncoated bilayered tablet 1 Tablet M/s Sun Pharma 8.58 Metformin contains: Laboratories Ltd. Hydrochoride Tablet Metformin Hydrochoride IP (as prolonged release) 500 mg Glimepiride IP 4 mg 21. Glimepiride + Each uncoated bilayered tablet 1 Tablet M/s Sun Pharma 9.78 Metformin contains: Laboratories Ltd. Hydrochoride Tablet Metformin Hydrochoride IP (as prolonged release) 1000mg Glimepiride IP 4 mg 22. Metformin HCL + Each uncoated bilayered tablet 1 Tablet M/s Eris Lifesciences 5.78 Gliclazide + contains: Ltd. Pioglitazone Tablets Metformin Hydrochoride IP (sustained release) 500 mg Gliclazide IP (sustained release) 30 mg Pioglitazone HCL eq. to Pioglitazone 15 mg 23. Metformin HCL + Each uncoated bilayered tablet 1 Tablet M/s Eris Lifesciences 8.29 Gliclazide + contains: Ltd. Pioglitazone Tablets Metformin Hydrochoride IP (sustained release) 500 mg Gliclazide IP (sustained release) 60 mg Pioglitazone HCL eq. to Pioglitazone 15 mg¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 21 24. Chlorthalidone + Each film coated tablet contains: 1 Tablet M/s Gkm New Pharma / 7.71 Telmisartan Tablet Chlorthalidone IP 6.25 mg M/s Torrent (Telsar CH 40/6.25) Telmisartan IP 40 mg Pharmaceuticals Ltd. 25. Chlorthalidone + Each film coated tablet contains: 1 Tablet M/s Gkm New Pharma / 8.03 Telmisartan Tablet Chlorthalidone IP 12.5mg M/s Torrent (Telsar CH 40/12.5) Telmisartan IP 40 mg Pharmaceuticals Ltd. 26. Chlorthalidone + Each film coated tablet contains: 1 Tablet M/s Gkm New Pharma / 13.91 Telmisartan Tablet Chlorthalidone IP 12.5mg M/s Torrent (Telsar CH 80/12.5) Telmisartan IP 80 mg Pharmaceuticals Ltd. 27. Divalproex Tablet Each film coated extended release 1 Tablet M/s Swiss Garnier 5.45 (Diwok OD 250 tablet contains: Biotech / M/s mg) Divalproex Sodium IP eq. to Wockhardt Ltd. Valproic Acid 250 mg 28. Voglibose + Each uncoated tablet contains: 1 Tablet M/s Eris Lifesciences 6.57 Metformin tablet Voglibose IP 0.2 mg Ltd. Metformin HCL IP 500 mg 29. Amoxycillin + Each combipack containing: 1 ML M/s Akums Drugs & 3.16 Potassium a) Amoxycillin and Potassium Pharmaceuticals Ltd. / Clavulnate Dry Clavulanate Oral Suspension IP M/s Blue Cross Syrup (Blumox-CA Each 5 ml suspension containing Laboratories Pvt. Ltd. Forte) Amoxycillin Trihydrate IP eq. to Amoxycillin 400 mg Potassium Clavulnate diluted IP eq. to Clavulanic Acid 57 mg b) 1 vial sterile water for injection IP Each vial containing Sterile water for injection IP 30 ml 30. Rosuvastatin + Each hard gelatin capsule contains: 1 Capsule M/s Synokem 17.88 Aspirin + Rosuvastatin Calcium IP eq. to Pharmaceuticals Ltd. / Clopidogrel Rosuvastatin 20 mg (as pellets) M/s Emcure Capsule Aspirin IP 75 mg (as enteric coated Pharmaceuticals Ltd. pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg (as pellets) 31. Rosuvastatin + Each hard gelatin capsule contains: 1 Capsule M/s Synokem 11.62 Aspirin + Rosuvastatin Calcium IP eq. to Pharmaceuticals Ltd. / Clopidogrel Rosuvastatin 10mg (as pellets) M/s Emcure Capsule Aspirin IP 75mg (as enteric coated Pharmaceuticals Ltd. pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (as pellets) 32. Diclofenac + Virgin Gel containing 1 GM M/s Akums Drugs & 2.41 Linseed Oil + Diclofenac Diethylamine BP 1.16% Pharmaceuticals Ltd. / Methyl Salicylate + w/w (eq. to Diclofenac Sodium 1% M/s Abbott Healthcare Menthol + w/w) Pvt. Ltd. Capsaicin Gel Virgin linseed Oil BP 3% w/w (Diclofam Hot) (containing predominantly Alpha Linolenic Acid) Methyl Salicylate IP 10% w/w Menthol IP 5% Capsaicin USP 0.0255w/w, Benzyl Alcohol IP 1%w/w 33. Clotrimazole + Ear drops contains: 1 ML M/s Akums Drugs & 5.27 Lignocaine Ear Clotrimazole IP 1.0% w/v Pharmaceuticals Ltd. / Drops (Triben) Lignocaine Hydrochloride IP 2.0% M/s Jenburkt w/v Pharmaceuticals Ltd. 34. Timolol + Each ml contains 5ML M/s Ajanta Pharma Ltd. 283.25 Brinzolamide Eye Brinzolamide IP 1.0 w/v Drops Timolol Maleate IP eq. to Timolol 0.5% w/v,22 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Benzalkonium Chloride IP 0.01% w/v (as preservative) 35. Diclofenac + Methyl Contains: Each Pack M/s Sun Pharmaceutical 125.00 + Menthol GEL Diclofenac Diethylamine BP 2.32% (20 gram) Industries Ltd. (Volini Maxx Gel) w/w (eq. to Diclofenac Sodium 2% w/w), Methyl Salcylate IP 10% w/w & Menthol IP 5% w/w 36. Diclofenac + Methyl Contains: Each Pack M/s Sun Pharmaceutical 187.50 + Menthol GEL Diclofenac Diethylamine BP 2.32% (30 gram) Industries Ltd. (Volini Maxx Gel) w/w (eq. to Diclofenac Sodium 2% w/w), Methyl Salcylate IP 10% w/w & Menthol IP 5% w/w 37. Olmesartan + Each film coated tablet contains: 1 Tablet M/s GKM New Pharma 9.585 Amlodipine + Olmesartan Medoxomil 20mg, Ltd. / M/s Unichem Chlorthalidone Tablet Laboratories Limited Chlorthalidone IP 6.25mg, (TRIOLSAR 20) Amlodipine Besylate IP eq. to Amlodipine 5mg tablets 38. Olmesartan + Each film coated tablet contains: 1 Tablet M/s GKM New Pharma 15.61 Amlodipine + Olmesartan Medoxomil 40mg, Ltd. / M/s Unichem Chlorthalidone Tablet Laboratories Limited Chlorthalidone IP 6.25mg, (TRIOLSAR 40) Amlodipine Besylate IP eq. to Amlodipine 5mg tablets 39. Losartan + Each film coated tablet contains: 1 Tablet M/s GKM New Pharma 6.36 Chlorthalidone + Losartan Potassium IP 50mg, Ltd. / M/s Unichem Amlodipine Tablet Laboratories Limited Chlorthalidone IP 6.25mg, (TRILOSAR 6.25 ) Amlodipine Besylate IP eq. to Amlodipine 5mg tablets 40. Losartan + Each film coated tablet contains: 1 Tablet M/s GKM New Pharma 6.41 Chlorthalidone + Losartan Potassium IP 50mg, Ltd. / M/s Unichem Amlodipine Tablet Laboratories Limited Chlorthalidone IP 12.50mg, (TRILOSAR 12.50) Amlodipine Besylate IP eq. to Amlodipine 5mg tablets 41. Darunavir + Each film coated tablet contains: 1 Tablet M/s Emcure 172.52 Ritonavir tablet Darunavir Ethanolate eq. to Pharmaceuticals Limited Darunavir 600mg and Ritonavir IP 100mg tablet 42. Telmisartan + Each uncoated bilayered tablet 1 Tablet M/s Aeon Formulations 8.91 Amlodipine + contains: Pvt. Ltd. / M/s USV Chlorthalidone Pvt. Ltd. Telmisartan IP 40 mg Tablet (Tazloc AC Amlodipine Besylate IP eq. to 12.5) Amlodipine 5 mg Chlorthalidone IP 12.5 mg 43. Darunavir + Each film coated tablet Contains: 1 Tablet M/s Mylan Laboratories 123.71 Ritonavir tablet Darunavir 400mg & Pvt. Ltd. / M/s Mylan (Durart – R 450) Pharmaceuticals Pvt. Ritonavir 50mg Tablets Ltd. 44. Diclofenac + Methyl Contains: 1 GM M/s The Madras 2.46 + Menthol Diclofenac Diethylamine BP Pharmaceuticals / M/s Salicylate + 1.16%w/w (eq. to Diclofenac Blue Cross Laboratories Menthol + Sodium 1%), Pvt. Ltd. Turpentine Oil Gel Methyl Salicylate IP 5% w/w, (Diclotal MR Gel) Mephenesin IP 85 5%w/w,¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 23 Menthol IP 2% w/w, Turpentine Oil BP 3%w/w 45. Lamivudine + Each film coated tablet contains: 1 Tablet M/s Emcure 114.06 Tenofovir + Lamivudine IP 300mg, Pharmaceuticals Dolugetravir tablet Limited Tenofovir Disoproxil Fumarate IP 300mg eq. to Tenofovir Disoproxil 245mg, Dolugetravir Sodium eq. to Dolutegravir 50mg. 46. Darunavir + Each film coated tablet contains: 1 Tablet M/s Hetero Labs 212.91 Ritonavir tablet Darunavir Ethanolate eq. to Limited / M/s Hetero (Danavir R) Darunavir 800mg, Healthcare Limited Ritonavir 100mg Tablet 47. Lamivudine + Each uncoated tablet contains: 1 Tablet M/s Mylan Laboratories 114.06 Tenofovir + Lamivudine IP 300mg, Limited / M/s Mylan Dolugetravir tablet Pharmaceuticals Private Tenofovir Disoproxil Fumarate IP (ACRIPTEGA) Limited 300mg, Dolugetravir Sodium eq. to Dolutegravir 50mg. 48. Daclatasvir + Each film coated tablet contains: 1 Tablet M/s Natco Pharma 556.442 Sofosbuvir tablet Daclatasvir Dihydrochloride eq. to Limited (HEPCINAT PLUS) Daclatasvir 60mg, Sofosbuvir 400mg 49. Daclatasvir + Each film coated tablet contains: 1 Tablet M/s Natco Pharma 556.442 Sofosbuvir tablet Daclatasvir Dihydrochloride eq. to Limited / M/s Cadila Healthcare Limited Daclatasvir 60mg, Sofosbuvir 400mg 50. Daclatasvir + Each film coated tablet contains: 1 Tablet M/s Mylan Laboratories 556.442 Sofosbuvir tablet Daclatasvir Dihydrochloride eq. to Pvt. Ltd. / M/s Mylan (MYHEP DVIR) Pharmaceuticals Pvt. Daclatasvir 60mg, Ltd. Sofosbuvir 400mg 51. Diclofenac + Methyl Contains: Each Pack M/s Sun Pharmaceutical 93.75 + Menthol GEL Diclofenac Diethylamine BP 2.32% (15 gram) Industries Ltd. (Volini Maxx Gel) w/w (eq. to Diclofenac Sodium 2% w/w), Methyl Salicylate IP 10% w/w & Menthol IP 5% w/w 52. Diclofenac + Methyl Contains: Each Pack M/s Sun Pharmaceutical 62.50 + Menthol GEL Diclofenac Diethylamine BP 2.32% (10 gram) Industries Ltd. (Volini Maxx Gel) w/w (eq. to Diclofenac Sodium 2% w/w), Methyl Salcylate IP 10% w/w & Menthol IP 5% w/w 53. Ceftriaxone 1 gm Each injection vial contains: 1 Vial M/s Innova Captab Pvt. 136.11 plus Tazobactum Ceftriaxone Sodium IP eq. to Ltd. / M/s Emcure 125 mg injection Pharmaceuticals Ltd Ceftriaxone 1 gm Tazobactum Sodium eq. to Tazobactum 125 mg 54. Cefpodoxime + Each 5 ml of the reconstituted 1 ML M/s Hetero Labs Ltd / 2.40 Potassium Dry suspension contains: M/s Cipla Limited Syrup Cefpodoxime Proxetil IP eq. to (Cefoprox CV) Cefpodoxime 50 mg Potassium Clavulanate Diluted IP eq.24 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] to Clavulanic Acid 31.25 mg 55. Cefpodoxime + Each 5 ml of the reconstituted 1 ML M/s Hetero Labs Ltd / 3.72 Potassium Dry suspension contains: M/s Cipla Limited Syrup Cefpodoxime Proxetil IP eq. to (Cefoprox CV) Cefpodoxime 100 mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 62.5mg Note: (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / marketeer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/192/60/2018/F. F. No. 8(60)/2018/D.P./NPPA-Div.-II] BALJIT SINGH, Asstt. Director Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054.

Continue your research

Related Documents from Ministry of Chemicals and Fertilizers